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SUMMARY 
 The innate immune system plays a central role in host defenses against invading pathogens. 
Innate immune cells sense the presence of pathogens through pattern recognition receptors that trigger 
intracellular signaling, leading to the production of pro-inflammatory mediators like cytokines, which 
shape innate and adaptive immune responses. Both by excess and by default inflammation may be 
detrimental to the host. Indeed, severe sepsis and septic shock are lethal complications of infections 
characterized by a dysregulated inflammatory response. 
 In recent years, members of the superfamily of histone deacetylases have been the focus of 
great interest. In mammals, histone deacetylases are broadly classified into two main subfamilies 
comprising histone deacetylases 1-11 (HDAC1-11) and sirtuins 1-7 (SIRT1-7). These enzymes 
influence gene expression by deacetylating histones and numerous non-histone proteins. Histone 
deacetylases have been involved in the development of oncologic, metabolic, cardiovascular, 
neurodegenerative and autoimmune diseases. Pharmacological modulators of histone deacetylase 
activity, principally inhibitors, have been developed for the treatment of cancer and metabolic 
diseases. When we initiated this project, several studies suggested that inhibitors of HDAC1-11 have 
anti-inflammatory activity. Yet, their influence on innate immune responses was largely 
uncharacterized. The present study was initiated to fill in this gap. 
 In the first part of this work, we report the first comprehensive study of the effects of HDAC1-
11 inhibitors on innate immune responses in vitro and in vivo. Strikingly, expression studies revealed 
that HDAC1-11 inhibitors act essentially as negative regulators of basal and microbial product-
induced expression of critical immune receptors and antimicrobial products by mouse and human 
innate immune cells like macrophages and dendritic cells. Furthermore, we describe a new molecular 
mechanism whereby HDAC1-11 inhibitors repress pro-inflammatory cytokine expression through the 
induction of the expression and the activity of the transcriptional repressor Mi-2β. HDAC1-11 
inhibitors also impair the potential of macrophages to engulf and kill bacteria. Finally, mice treated 
with an HDAC inhibitor are more susceptible to non-severe bacterial and fungal infection, but are 
protected against toxic and septic shock. Altogether these data support the concept that HDAC1-11 
inhibitors have potent anti-inflammatory and immunomodulatory activities in vitro and in vivo. 
 Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that plays a 
central role in innate immune responses, cell proliferation and oncogenesis. In the second part of this 
manuscript, we demonstrate that HDAC1-11 inhibitors inhibit MIF expression in vitro and in vivo and 
describe a novel molecular mechanism accounting for these effects. We propose that inhibition of MIF 
expression by HDAC1-11 inhibitors may contribute to the antitumorigenic and anti-inflammatory 
effects of these drugs. 
 NAD+ is an essential cofactor of sirtuins activity and one of the major sources of energy 
within the cells. Therefore, sirtuins link deacetylation to NAD+ metabolism and energy status. In the 
last part of this thesis, we report preliminary results indicating that a pharmacological inhibitor of 
SIRT1-2 drastically decreases pro-inflammatory cytokine production (RNA and protein) and interferes 
with MAP kinase intracellular signal transduction pathway in macrophages. Moreover, administration 
of the SIRT1-2 inhibitor protects mice from lethal endotoxic shock and septic shock. 
  
 Overall, our studies demonstrate that inhibitors of HDAC1-11 and sirtuins are powerful anti-
inflammatory molecules. Given their profound negative impact on the host antimicrobial defence 
response, these inhibitors might increase the susceptibility to opportunistic infections, especially in 
immunocompromised cancer patients. Yet, these inhibitors might be useful to control the 
inflammatory response in severely ill septic patients or in patients suffering from chronic 
inflammatory diseases.  
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ABBREVIATIONS 
Ad Adenovirus 
AKT AKR mouse T-cell lymphoma (serine/threonine protein kinase) 
BMDC Bone marrow-derived dendritic cell 
BMDM Bone marrow-derived macrophage 
CARD Caspase-recruiting domain 
ChIP Chromatin immunoprecipitation 
CLP Cecal ligation and puncture 
CLR C-type lectin receptor 
COX-2 Cyclooxygenase 2 
CpG Cytosine-phosphate-guanosine 
CRE cAMP responsive element 
CREB CRE-binding protein 
DAMP Danger associated molecular pattern 
DC Dendritic cell 
DDT D-dopachrome tautomerase 
dsRNA Double-stranded ribonucleic acid 
DUSP Dual-specific phosphatase 
ELISA Enzyme-linked imunosorbent assay 
ERK Extracelluar signal regulated kinase 
ETS E26 transformation specific 
FOXO Forkhead-containing protein type O 
HAT Histone acetyl-transferase 
HDAC Histone deacetylase 
IC50 Half maximal inhibitory concentration 
IFN Interferon 
IκB Inhibitor of κB 
IL Interleukin 
IL-1R Interleukin-1 receptor 
IRAK IL-1 receptor associated kinase 
IRF Interferon regulatory factor 
JNK c-Jun N-terminal Kinase 
LGP2 Laboratory of genetics and physiology 2 
LPS Lipopolysaccharide 
LRR Leucine-rich repeat 
MAL MyD88 adaptor-like protein (also named TIRAP) 
MAPK Mitogen activated protein kinase 
MD-2 Myeloid differentiation-2 
MHC-II Major histocompatibility complex class II molecule 
MIF Macrophage migration inhibitory factor 
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MKP MAPK phosphatase 
moDC Monocyte-derived debdritic cell 
mRNA Messenger ribonucleic acid 
MyD88 Myeloid differentiation factor 88 
NaB Sodium butyrate 
NAD+/NADH Nicotinamide adenine dinucleotide (oxidized/reduced) 
NALP NACHT domain-, leucine-rich repeat-, and PYD-containing protein 
Nam Nicotinamide 
NAMPT Nicotinamide phosphoribosyltransferase/PBEF/Visfatin 
 
P 
NBD Nucleotide-binding domain 
NF-κB Nuclear factor-κB 
NLR NOD-like receptor 
p38 p38 mitogen-activated protein kinase 
Pam3CSK4 Palmitoyl-cys((RS)-2,3-di(palmitoyloxy)-propyl)-Ser-Lys-Lys-Lys-Lys-OH 
PAMP Pathogen-associated molecular pattern 
PBMC Peripheral blood mononuclear cell 
PI3K Phosphatidylinositol 3 kinase 
PRR Pattern recognition receptor 
RIG-I Retinoic acid-inducible gene-I 
RLR RIG-like receptor 
RT-PCR Real-time polymerase chain reaction 
SIRT Sirtuin (mammalian homolog of SIR2) 
SIR2 Silent information regulator 2 
ssRNA Single-stranded ribonucleic acid 
TIR Toll/Interleukin-1 receptor 
TIRAP Toll/Interleukin-1 receptor domain containing adaptor (also named MAL) 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TRAF Tumor necrosis factor receptor-associated factor 
TRIF TIR-domain-containing adaptor inducing interferon β 
TSA Trichostatin A 
SAHA Suberoylanilide hydroxamic acid 
STAT Signal transducer and activator of transcription 
VPA Valproic acid 
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1 INTRODUCTION 
1.1 Innate immunity 
The innate immune system plays a crucial role in host defenses against invading 
microorganisms. The innate immune system is activated as soon as a pathogen crosses the host 
external defense barriers, lasts for a few hours, and usually results in the elimination of the invading 
microorganism. Detection of microbial pathogens is first carried out by phagocytic sentinel cells 
located in tissues in direct contact with the host’s natural environment (monocytes/macrophages and 
immature dendritic cells) or that are rapidly recruited to the site of infection (neutrophils). This 
process involves coordinated actions of soluble and cellular molecules comprising components of the 
complement system, acute phase proteins such as the lipopolysaccharide (LPS) binding protein (LBP), 
extracellular or intracellular pattern-recognition types of molecules including the Toll-like receptors 
(TLRs), the nucleotide-binding oligomerization domain-like receptors (NLRs), retinoic acid-inducible 
gene-I (RIG-I)-like receptors (RLRs), C-type lectin receptors (CLRs) and scavenger receptors. 
Recognition of invasive pathogens by immune cells relies on their capacity to detect microbial 
molecular motifs (i.e. microbial- or pathogen-associated molecular patterns, PAMPs) via microbial- or 
pathogen-recognition receptors/molecules (PRRs) (Figure 1.1) (1-3).  
 
 
Figure 1.1. Pattern recognition receptors (PRRs).  In response to microbial products, distinct families of 
receptors trigger intracellular signaling cascades that lead to immune responses planned to eradicate invading 
pathogens. Toll-like receptors (TLRs), C-type lectin receptors (CLR), RIG-I-like receptors (RLRs) and 
nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) recognize molecular patterns derived 
from bacteria, viruses, protozoa and fungi. 
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1.2 Toll-like receptors 
TLRs recognize a broad spectrum of microbial products (Table 1.1). Thirteen members of the 
TLR family (TLR1-13) have been identified within human and mouse genomes, but only TLR1-10 are 
expressed in human. TLR4 was the first discovered and remains the most studied TLR. TLR4 is 
involved in the sensing of LPS, a pro-inflammatory component of the outer membrane of Gram-
negative bacteria. TLR4 forms a complex with MD-2 on the cell surface and both of these proteins are 
necessary in the recognition of the lipid chains of LPS. The plasmatic LPS-binding protein (LBP) 
binds to the lipid A moiety of LPS and transfers LPS to CD14. CD14 is a glycophosphatidylinositol-
anchored protein expressed on the surface of myeloid cells that binds to LBP and delivers the LBP-
LPS complex to the TLR4-MD-2 complex. Finally, TLR4 provides the signal transduction of the LPS 
receptor complex. 
TLR2 is involved in the sensing of a broad array of microbial products among which bacterial 
lipopetides and peptidoglycan sub-components and fungal mannans and glucans. TLR2 forms 
homodimers and heterodimers with TLR1 and TLR6. Homodimers of TLR2 recognize, for example, 
peptidoglycan, lipoteichoic acid (LTA) from Gram-positive bacteria. The TLR1/2 heterodimer is 
involved in the recognition of triacyl lipopeptides (Pam3CSK4) from Gram-positive bacteria and 
mycobacteria and the TLR2/6 heterodimer recognizes diacyl lipopetides from mycoplasma, LTA from 
Streptococcus and zymosan from Saccharomyces (4,5)). The recognition of certain microbial products 
by TLR2 involves the participation of co-receptors such as CD14, CD36 and Dectin-1 (5). 
TLR5 is implicated in the detection of flagellin, a constituent of flagella from bacteria. The 
last TLR expressed on cell surface is TLR11. TLR11 is involved in the recognition of uropathogenic 
bacteria and profilin-like molecules in mice. Of note, TLR11 is thought to be non-functional in human 
due to a stop codon in its sequence. TLR3, TLR7, TLR8 and TLR9 reside in the intracellular vesicles 
(endoplasmic reticulum (ER), endosomes, lysosomes and endolysosomes) and are responsible for the 
recognition of microbial nucleic acids. TLR3 recognizes both viral single- and double-stranded RNA. 
TLR7 and TLR8 recognize viral single-stranded RNA. TLR9 detects viral double-stranded DNA, 
sequence specific unmethylated CpG motifs expressed in DNA from bacteria and viruses and also 
hemozoin from Plasmodium (5). TLR12 and TLR13 are expressed in mouse but their function remains 
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poorly defined. 
 
Table 1.1. Toll-like receptors, their ligands and adaptor molecules.  Adapted from Kumar et al., Biochemical 
and Biophysical Research Communications, 2009 (5). 
 
TLR Location PAMPs recognized Origin of ligands Signaling adaptors 
TLR1/2 Plasma membrane  Triacyl-lipopeptide Bacteria, Mycobacteria MAL/TIRAP, MyD88 
TLR2 Plasma membrane Peptidoglycan 
Lipoteichoic acid 
Zymosan 
Gram-positive bacteria 
Fungi 
MAL/TIRAP, MyD88 
TLR3 Endosome ssRNA and dsRNA 
Poly(I:C) 
Viruses 
Synthetic 
TRIF 
TLR4 Plasma membrane 
 
LPS 
Mannan 
Glycoinosiolphospholipids 
F-protein 
Envelope 
Gram-negative bacteria 
Candida 
Trypanosoma 
RSV, MMTV 
MAL/TIRAP, MyD88, 
TRAM and TRIF 
TLR5 Plasma membrane Flagellin Flagelated bacteria MyD88 
TLR6/2 Plasma membrane 
 
Diacyl lipopeptides 
LTA 
Zymosan 
Mycoplasma, bacteria 
Gram-positive bacteria 
Saccharomyces 
MAL/TIRAP, MyD88 
 
TLR7 Endosome ssRNA 
Imidazoquinolines (imiquimod, 
R848) and nucleosides analogues 
Viruses 
Synthetic compounds 
MyD88 
TLR8 Endosome ssRNA 
Imidazoquinolines (R848) 
Viruses 
Synthetic compounds 
MyD88 
TLR9 Endosome Unmethylated CpG DNA Bacteria, fungi, virus MyD88 
TLR11 
(mouse) 
Plasma membrane Profilin, Uropathogenic E. coli 
Chromatin Ig-G complexes 
Bacteria , yeasts, viruses 
Host 
MyD88 
 
 
1.3 Signaling through Toll-like receptors 
The N-terminal extracellular domain of TLRs, which is composed 16-28 leucine-rich repeats 
(LRRs), is responsible for the recognition of PAMPs. The intracellular domain triggers downstream 
signaling and is composed of a Toll/IL-1 receptor domain (TIR). TIR domain is responsible for the 
recruitment of adaptor molecules that in turn will initiate intracellular signaling cascades (Figure 1.2). 
All TLRs excepted TLR3 interact with the adaptor myeloid differentiation primary response protein 
88 (MyD88) (Table 1.1). TLR1, TLR2, TLR4 and TLR6 recruit in addition to MyD88 the linker 
protein TIR domain-containing adaptor protein (TIRAP also known as MAL) that bridges TIR 
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domains from TLRs and MyD88. Ligand binding by TLR3 and TLR4 recruits TIR domain-containing 
adaptor inducing interferon-β (TRIF also named TICAM-1). TLR4 recruits TRIF trough TRIF-related 
adaptor molecule (TRAM or TICAM-2) that bridges between TIR domains of TLRs and TRIF. 
MyD88 activates the IL-1 receptor associated kinase (IRAK) family that leads to the activation of 
TNF receptor-associated factor (TRAF) 6. TRAF6 promotes activation of TGF-beta-activated kinase 
(TAK) 1 that in turn activates inhibitor of κB (IκB) kinase (IKK) and mitogen-activated protein 
kinases (MAPKs) which lead to the activation of nuclear factor-κB (NF-κB) and activator protein-1 
(AP-1) transcription factors, respectively (5). Activation of IRAK-1 via TLR7, TLR8 and TLR9 leads 
to phosphorylation and subsequent activation of interferon (IFN) regulatory factor (IRF) 1, IRF5 and 
IRF7. TLR3 and TLR4 signal leads in the production of type I IFNs. TRIF activates TRAF3 that 
serves as a linker to TBK1, which phosphorylates and activates the transcription factor IRF3. IRF3 is 
responsible for the induction of type I IFNs. TRIF can also activate the NF-κB and MAPK pathways 
via interaction with RIP1 that activates TAK1 (Figure 1.2) (2,5).  
 
Figure 1.2. Toll-like receptor signaling.  TLR1, 2, 4, 5, 6 and 11 are located on cell surface. TLR3, 7, 8 and 9 
are located in endosomes. All TLRs, except TLR3, recruit the adaptor protein MyD88 through their TIR-domain. 
TLR3 and TLR4 also recruit TRIF. 
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AP-1, NF-κB and IRF transcription factors promote the rapid expression of numerous 
immune-related genes leading to the production and release of cytokines, among which tumor necrosis 
factor (TNF), interleukins (IL)-1, IL-6, IL-8, IL-10, IL-12 and IL-18, chemokines and IFNs, together 
with the up-regulation of cell surface molecules, such as major histocompatibility class II (MHC II), 
adhesins, selectins, integrins and co-stimulatory molecules. All these events are involved in the 
development of an inflammatory response, which is essential to coordinate the cellular and humoral 
responses intended to contain or eradicate invasive microorganisms (6). 
1.4 RIG-like receptors, NOD-like receptors and C-type lectin receptors 
RLRs are specialized in the recognition of viral RNA present in the cytoplasm, thus triggering 
the transcription of type I IFNs as well as pro-inflammatory cytokine genes (Figure 1.1). The RLR 
family is composed of three members: RIG-I, melanoma differentiation associated gene 5 (MDA5) 
and laboratory of genetics and physiology 2 (LGP2). RIG-I binds 5’-triphosphate of ssRNAs and short 
dsRNAs whereas MDA5 detects longer dsRNAs and poly-IC. RIG-I have been involved in the sensing 
of paramyxoviruses (Sendai virus and Newcastle disease virus), orthomyxoviruses (influenza virus), 
rhabdoviruses (vesicular stomatitis virus) and flaviviruses (Japanese encephalitis virus and hepatitis C 
virus), and MDA-5 in the sensing of picornaviruses (encephalomyocarditis virus, Theiler’s virus, and 
Mengo virus) family. West Nile and Dengue viruses (Flaviviruses) and reoviruses are detected by both 
RIG-I and MDA-5. LGP2 acts as an inhibitor of RIG-I and MDA-5 by binding to their RNA binding 
domain, but can also act in some circumstances as a positive regulator of MDA5 in the recognition of 
specific viruses (2,7). 
Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) are located in the 
cytosol and detect a broad range of PAMPs and danger-associated molecular patterns (DAMPs) from 
both endogenous and exogenous origins. NLRs are constituted of three domains: a N-terminal protein 
interaction domain, a central nucleotide binding domain and a C-terminal leucine-rich repeat (LRR). 
Members of the NLR family are classified into subcategories according to their N-terminal protein 
interaction domain which are acidic transactivation domain (NLRA), baculovirus inhibitor of 
apoptosis protein repeat [BIR] (NLRB), CARD (NLRC), pyrin domain (NLRP) or unknown domain 
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(NLRX). NOD1 and NOD2 (also called NLRC1 and NLRC2, respectively) are able to recognize 
components of peptdioglycan (PGN). NOD1 recognizes γ-D-glutamyl-meso-diaminopimelic acid (iE-
DAP) and NOD2 muramyl dipeptide (MDP), which is the main constituent of PGN motif. NOD1 and 
NOD2 sensing of bacterial cell wall activates signaling via MAPK and NF-κB that results in the 
production of inflammatory cytokines and anti-microbial proteins (2) (Figure 1.1).  
NLRs respond to PAMPs or DAMPs and promote the release of bioactive cleaved IL-1β and 
IL-18 after the assembly of “inflammasomes”. NLRs forming inflammasomes are NALP1 (NLRP1), 
NALP3 (NLRP3), IPAF (NLRC4) and NAIP (NLRB) (2). Signaling occurs between PYD or CARD 
domains of NLRP1, NLRP3 and IPAF and the PYD domain of the adaptor molecule ASC that, 
through its CARD domain, interacts with and activates pro-caspase-1 into caspase-1. Finally, activated 
caspase-1 cleaves pro-IL-1β and pro-IL-18, leading to the secretion of bioactive IL-1β and IL-18 
(Figure 1.1). 
CLRs are another class of transmembrane PRRs (Figure 1.1). They are involved in the 
recognition of a wide range of pathogens including bacteria, fungi, viruses and parasites. Some 
representatives of this class are dectin-1 that recognizes β-glucans and dectin-2 that recognizes 
mannose from yeast and bacteria. Recognition of pathogens by CLRs induces the production of pro-
inflammatory cytokines, promotes phagocytosis and stimulates the respiratory burst. Signaling occurs 
through the ITAM domain of dectins or their associated signaling partners. ITAM promotes 
phosphorylation of SYK that activates CARD9, which activates the NF-κB and MAPKs signaling 
pathways (8). 
1.5 Innate Immunity, sepsis and septic shock 
The regulation of innate immune responses has to be tightly controlled in order to coordinate 
the cellular and humoral responses intended to contain or eradicate invasive microorganisms. If the 
host fails to mount a sufficient inflammatory response, microbes will proliferate, compromising host 
integrity. Conversely, an overwhelming inflammatory response will lead to a cascade of events 
leading to shock, multiple organ failure and often death (Figure 1.3). 
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Severe sepsis and septic shock are life-threatening complications of infections. Sepsis is defined 
as a systemic inflammatory response syndrome (SIRS) with a known or suspected source of infection. 
Severe sepsis is characterized by organ dysfunction, and septic shock by vasopressor-resistant 
hypotension (9). Mortality associated with severe sepsis and septic shock is considerable, ranging 
from 20-35% in the case of severe sepsis to 50-80% for septic shock (10). Severe sepsis and septic 
shock are the leading cause of death in non-coronary intensive care units. It is consequently of primary 
interest to develop treatments blocking or controlling the overwhelming inflammatory responses in 
order to decrease morbidity and mortality related to the early phase of sepsis (11,12). The control of 
the expression of cytokines is therefore a key aspect from a therapeutic point of view. 
 
Figure 1.3. Sepsis, a dysregulated inflammatory response to infection.  Host immune response to infection 
usually leads to pathogen elimination, tissue healing and full recovery. Sepsis is characterized in its early phase 
by an overwhelming inflammatory response which is involved in tissue damage, vascular collapse and multiple 
organ failure. Late phase of sepsis is characterized by a state of immune suppression that favors the development 
of secondary life-threatening infections. Adapted from Van der Poll T & Opal SM, Lancet Infectious Diseases 
2008 (11). 
 
1.6 Chromatin dynamics and modifications 
Chromatin is a highly ordered structure mainly composed of DNA and histones proteins. 
Condensed chromatin, also called heterochromatin, is associated with non-transcribed regions of the 
genome such as telomeres, centromeres and silenced genes. The condensation or packaging is a 
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necessity in terms of space improvement within the nucleus and it allows strengthening of DNA 
during mitosis and meiosis (Figure 1.4). On the contrary, euchromatin is defined as relaxed and 
accessible chromatin, essentially found in transcribed regions of the genome. 
A 
 
B 
 
Figure 1.4. Nucleosome histone core and chromatin structure.  (A) Histone proteins H2A, H2B, H3 and H4 
compose the core of the nucleosome. Histone N-terminal tails protrude through DNA wrapped around the 
histone core. Histone tails contain lysine residues (K) that accommodate post-translational modifications. Here 
are represented the lysine residues known to be acetyated in a reversible manner. (B) Histone octamers around 
which DNA is wrapped compose a dynamic structure with the ability to compact and decompact DNA. 
 
 
1.6.1 Histone proteins and nucleosomes 
Histones are acidic proteins forming octamers of two histone 2A (H2A), H2B, H3 and H4 
subunits, around which 147 bp DNA is wrapped in 1.67 turns. The DNA-histone octamer complex is 
called nucleosome and is the first scaffold for DNA compaction. H3 and H4 (and H2B to a lesser 
extent) from adjacent nucleosomes can interact with each other through their N-terminal tails that 
protrude throughout DNA (13,14). These interactions are made possible by post-translational 
modifications predominantly on the amino-terminal tails of histones. Post-translational modifications 
of histones especially on lysine, arginine and serine residues of H2B, H3 and H4 tails such as 
acetylation, methylation, phosphorylation, ubiquitination, sumoylation, ADP-ribosylation, and 
deimination (citrullination) mediate interactions between histone tails and control the turnover of 
histones. These modifications are catalyzed by pairs of enzymes with opposing activities, adding or 
removing functional groups (15). Histone modifications were stated about ten years ago to form an 
epigenetic marking system called the “histone code” (16,17) where a modification or a pattern of 
modifications dictate the ability of other proteins to “read” the code and promote changes in the 
chromatin dynamics. Combinatorial modifications of histones likely reflect a given task, but efforts 
made to resolve a predictable code remains largely unsuccessful. Yet, this code is now commonly 
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accepted to influence the chromatin-associated processes under normal and pathological situations 
(18). 
1.6.2 Chromatin modifications 
Chromatin can be modified through two major ways. First, histones can be replaced, ejected or 
sled along DNA. Second, histones can undergo post-translational modifications. All these events may 
occur at the same time in a dynamic manner. It takes only few minutes for the cell to react to a 
stimulus and apply these mechanisms to modify the chromatin. The major functions for these 
processes are the interruption of contact between nucleosomes (decompaction) and the allowance for 
the recruitment of transcription regulators or, conversely, the compaction of nucleosomes and 
undocking of transcription regulators (Figure 1.5). This results in the partition of the genome into 
heterochromatin and euchromatin in order to regulate the expression of large subsets of genes. These 
modifications also act at the local level, particularly on the promoter of highly regulated genes, 
providing a supplementary level of fine-tuning of gene transcription (15). 
1.6.3 Regulation of transcription through histone modifications 
The main histone modifications affecting transcription rate are methylation (lysine and 
arginine), acetylation (lysine) and sumoylation (lysine) of H3 and H4 and ubiquitination of H2A and 
H2B. Distribution of histone modifications along a given gene is not arbitrary and correlates with its 
transcription rate as revealed by experiments of ChIP followed by gene-array expression (ChIP on 
chip). For example, acetylated H3 and H4 containing nucleosomes are usually located in the promoter 
region of actively transcribed genes. The same correlation can be found with tri-methylated H3 at 
lysine 4 (H3K4me3). On the contrary, H3K27me is associated with inactive transcription (19). 
Histone variants are also involved in the regulation of transcription but this topic will not be dealt with 
in subsequent studies. Regulation of transcription by chromatin modification and remodeling is not 
restricted to the recruitment of transcription regulators. It has also been described to affect 
transcription initiation and elongation (19). 
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1.6.4 Acetylation of histone proteins 
Acetylation of lysine residues on the tails of H3 and H4 histones is associated with relaxed 
transcriptionnally active chromatin (20,21), whereas hypo-acetylated histones are commonly 
associated with condensed chromatin of silent regions of the genome (22) (Figure 1.5). Acetylation of 
H3 and H4 brings negative charges that neutralize the positively charged core of histones, 
consequently hampering the interaction between histone tails and phosphate groups of DNA (23). The 
acetylation of histones is catalyzed by proteins that possess histone acetyltransferase (HAT) activity, 
such as CREB binding protein (CREBBP or CBP), E1A binding protein p300 (EP300 or p300), 
P300/CBP-associated factor (PCAF), general control of amino acid synthesis protein-like 5 
(GCN5/KAT2A) and 60kDa Tat-interacting protein (TIP60/KAT5) (18). CBP/p300, PCAF/GCN5, 
and HATs in general are regulators of DNA transcription, replication, repair and condensation (15). 
On the contrary, histone deacetylases (HDACs) deacetylate histones H3 and H4 on lysine residues of 
their N-terminal tails that make them “stick” to DNA. 
 
Figure 1.5. Chromatin structure and transcriptional activity.  Recruitment of complexes with HAT activity 
allows histone acetylation and thus decompaction of DNA and recruitment of transcription regulators. 
Recruitment of HDACs to promoter regions promotes deacetylation of histones, DNA compaction and exclusion 
of transcription regulators. Ac: acetylation, HAT: histone acetyltransferase, HDAC: histone deacetylase M: 
methylation, TF: transcription factor. 
 
1.6.5 Histone deacetylases (HDACs) 
HDACs catalyze the cleavage of acetyl groups from lysine residues of histone H3 and H4 as 
well as non-histone proteins. Eighteen mammalian HDACs have been identified and classified into 
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four classes based on their homology with yeast HDACs (24) as well as their subcellular localization 
and their enzymatic activity (25) (Figure 1.6). 
 
 
Figure 1.6. Classification of mammalian histone deacetylases (HDACs) according to their enzymatic 
activity and sub-cellular localization. Class I HDACs are localized in nucleus, class IIa and IIb in nucleus and 
cytoplasm and class IV predominantly in the nucleus. Class IIb HDACs possess two catalytic sites. Adapted 
from Bolden et al., Nature Reviews Drug Discovery, 2006 (31). 
 
Class I HDACs are homologues of yeast Rpd3 and include HDACs 1, 2, 3 and 8 and are found 
uniquely in the nucleus of most cell lines and tissues. Class IIa contains HDACs 4, 5, 7 and 9. Class 
IIb includes HDACs 6 and 10, which are closely related to class IIa enzymes, but possess two 
deacetylation catalytic sites (one of which is inactive in HDAC10). Classes II are related to yeast Hda1 
and can be found in both the nucleus and the cytoplasm of some cell types. Classes I and II are Zn2+-
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dependent enzymes. Class IV, solely represented by HDAC11, has only been recently characterized 
(Figure 1.6) (26). Class III enzymes are related to the yeast Sir2p and are called sirtuins (SIRT) or 
sir2-like proteins (see chapter 6). Sirtuins are NAD+-dependent enzymes. Of note they are not 
sensitive to inhibitors of classes I, II and IV HDACs. Like other HDACs, sirtuins can deacetylate 
lysines of non-histone proteins (27). 
1.6.6 Physiology of class I, II and IV HDACs 
Class I HDACs are generally found in repressive complexes such as Sin3, NuRD, CoREST, 
PRC2 and N-CoR-SMRT. Class I HDACs play a critical role in development (32). Eventhough their 
closey related structure and function might let one anticipate functional redundancy, null-phenotype of 
each class I HDAC results in non-viable mice (Table 1.2). Class IIa HDACs possess a reduced 
enzymatic activity and mainly function as adaptors recruiting transcriptional regulators as well as class 
I HDACs. Class IIa HDACs are involved in skeletogenesis and cardiovascular growth and function, 
regulate muscle differentiation and control endothelial function (32). As a main tubulin deacetylase, 
the class IIb HDAC6 regulates cytoskeleton dynamic (33). Like class IIa HDACs, class IV HDAC11 
is expressed in heart, brain and muscle; however its precise function remains to be determined.  
Table 1.2. HDACs, loss of function phenotypes in mice and time point of lethality of knockouts. Adapted 
from Haberland et al. 2009 (32). 
 
Class HDAC Time of lethality Phenotype 
HDAC1 Embryon, day 10.5 Proliferation defects 
HADC2 Postnatal, day 1 Cardiac malformation 
HDAC3 Embryon, day 9.5 Gastrulation defects 
Class I 
HDAC8 Postnatal, day 1 Craniofacial defects 
HDAC4 Postnatal, day 7-14 Chondrocyte differentiation defect in growth plate 
HDAC5 Viable Exacerbated cardiac hypertrophy after stress 
HDAC7 Embryon, day 11 Endothelial dysfunction 
Class IIa 
HDAC9 Viable Exacerbated cardiac hypertrophy after stress 
HDAC6 Viable Increased tubulin acetylation Class IIb 
HDAC10 Not determined - 
Class IV HDAC11 Not determined - 
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Dysregulation of HDAC expression or activity has been involved in a variety of pathological 
disorders such as cancer, metabolic and inflammatory diseases (28-30). As it will be discussed later, 
modulators of HDAC activity are of great interest as they could be used to interfere with numerous 
diseases. For example, small molecules inhibiting class I, II and IV HDACS are among the most 
promising anti-cancer drugs under development. 
1.6.7 Non-histone targets of HDACs 
HDACs deacetylate a wide range of non-histone proteins including transcription factors, 
chaperones, nuclear receptors, transcription co-regulatory proteins, cell-cycle progression and cell 
death proteins and this list is in constant expansion (34). In fact non-histone proteins are the major 
targets for HDACs. Recently, a novel nomenclature has been proposed to denominate enzymes 
modifying histone lysines. HATs, histone methyltransferases (HMTs) and histone demethylases 
(HDMs) would be renamed K-acetyltransferases (KATs), K-methyltransferases (KMTs) and K-
demethylases (KDM), respectively. In order to avoid confusion, HDACs and PRMTs (protein arginine 
N-methyltransferases) have not been renamed (35). 
Like phosphorylation, protein acetylation is recognized as playing very important roles in 
cellular signaling at multiple levels. Directly or indirectly, acetylation regulates protein localization, 
stability, enzymatic activity and DNA binding activity, protein-protein interactions, gene expression 
and mRNA stability (36). Of note, acetylation can have dual effects on the function of a given protein 
(for example increased or decreased NF-κB p65 DNA binding, see Table 1.3). Altogether, these 
multiple levels of action situate acetylation as a master switch as important as phosphorylation (37). 
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Table 1.3. Consequences of proteins modification by acetylation.  Adapted from Spange et al., The 
International Journal of Biochemistry & Cell Biology, 2009 (36). 
 
Biological process Consequence of protein acetylation 
 Increase Decrease 
Protein stability p53, p73, Smad7, c-Myc, Runx3, AR, H2A.z, 
E2F1, NF-E4, ER81, SREBP1a, HNF6, BACE1 
GATA1, HIF-1α, pRb, SV40 T-Ag 
DNA binding p53, SRY, STAT3, GATA transcription factors, 
E2F1, p50 (NFκB), Er, p65 (NF-κB), c-Myb, 
MyoD, HNF-4, AML1, BETA2, NF-E2, 
KLF13, TAL1/SCL, TAF(I)68, AP 
endonuclease 
YY1, HMG-A1, HMG-N2, p65 (NF-κB), 
DEK, KLF13, 
Fen-1 
Gene expression 
(Transcriptional 
activation or 
inactivation) 
 
p53, HMG-A1, STAT3, AR, ERα (basal), 
GATA, EKLF, MyoD, E2F1, p65 (NFκB), GR, 
p73, PGC1α, MEF2D, GCMa, PLAG1, 
PLAGL2, Bcl-6, β-catenin, KLF5, Sp1, BETA2, 
Cart1, RIP140, TAF(I)68 
Erα (ligand-bound), HIF-1α, STAT1, 
FOXO1, 
FOXO4, RIP140 
Protein interactions STAT3, AR, EKLF, Importin A, STAT1, 
TFIIB, α-tubulin, actin, cortactin 
p65 (RelA), Ku70, Hsp90 
 
Localisation   nucleus 
PCAF, SRY, CtBP2, POP-1, HNF-4, PCNA 
  cytosol 
c-Abl, p300, PAP 
mRNA stability p21, Brm Tyrosinhydrolase (Th), eNOS 
Enzymatic activity p300, ATM PTEN, HDAC1, Mdm2, ACS, Neil2, Polβ 
Expression of viral 
proteins 
E1A, S-HDAg, L-HDAg, HIV Tat, SV40 T-Ag 
 
 
1.7 Histone deacetylase inhibitors 
1.7.1 Discovery and mechanisms of action 
HDAC inhibitors from natural or synthetically origins can be classified into five groups 
according to their structure: hydroxamate derivatives, cyclic peptides, aliphatic acids, benzamides and 
ketones (Table 1.4). Sodium butyrate (NaB) was the first identified HDAC inhibitor (38). This 
aliphatic acid is a by-product of dietary fibers anaerobic fermentation. NaB suppresses deacetylation 
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of histones H3 and H4 and increases the sensitivity of DNA to DNase I (39). NaB inhibits the growth 
and promotes the differentiation and the apoptosis of cancer cells (40,41). Valproic acid (VPA) is 
closely related to butyrate and belongs to the same class of short-chain fatty acids HDAC inhibitors. 
VPA specifically inhibits the catalytic activity of class I HDACs and induces proteasomal degradation 
of HDAC2 (42). As NaB, VPA induces the differentiation and apoptosis of carcinoma cells. VPA 
inhibits cancer development and metastasis in animal models (42,43). VPA increases brain-derived 
neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), thereby playing a 
neuroprotective role (44). VPA is used to treat epilepsy and bipolar disorders. Trichostatin A (TSA) is 
an organic compound of the hydroxamate family first isolated as an antifungal antibiotic from 
Streptomyces hygroscopus. TSA is a potent inhibitor of class I and class II HDACs in vitro and in vivo 
(39). Like NaB and VPA, TSA exhibits anti tumorigenic effects. It induces the differentiation, inhibits 
the growth and promotes and apoptosis of numerous tumors among which leukemia and glioblastoma 
(45,46). TSA has not reached the clinics owing to its toxicity. Yet, it remains extensively used in 
research as a prototypical powerful HDAC inhibitor. Moreover, the structure of TSA was used to 
synthesize suberoylanilide hydroxamic acid (SAHA), a hydroxamate compound which, like TSA, 
inhibits class I and II HDACs. The inhibitory mechanism of SAHA is similar to that of TSA: it binds 
directly to the Zn catalytic pocket of HDACs and mimics a lysine residue (47). SAHA has effective 
anticancer activity against hematologic and solid tumors. Recently, FDA has approved SAHA 
(vorinostat) to treat cutaneous T-cell lymphomas (48). Overall, HDAC inhibitors have shown good 
safety profiles in patients with solid and hematologic tumors and are amongst the most encouraging 
anti-cancer drugs under development (27,31,49-51). Great efforts are devoted to design novel 
inhibitors of HDACs with increased specificity and activity. These molecules will allow fine tuned 
analyses of the role of each HDAC under physiological and pathological conditions. More 
importantly, they will offer new therapeutic anti-cancer therapies, especially for patients with tumors 
resistant to conventional therapies (52). 
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Table 1.4. HDAC inhibitors. Adapted from Bolden et al., Nature Reviews Drug Discovery, 2006 (31). 
Class Compound Concentration range of 
activity 
HDAC specificity 
Short-chain fatty 
acid 
Butyrate 
Valproic acid (VPA) 
mM 
mM 
Class I, IIa 
Class I, IIa 
Hydroxamate Trichostatin A (TSA) 
Suberoylanilide hydroxamic 
acid 
PXD101 
LAQ824 
LBH589 
Pyroxamide 
Tubacin 
SK-7041 
SK-7068 
nM 
µM 
µM 
nM 
nM 
µM 
µM 
nM 
nM 
Class I, II 
Class I, II 
Class I, II 
Class I, II 
Class I, II 
Class I (Class II unknown) 
Class IIb 
HDACs 1 and 2 
HDACs 1 and 2 
Benzamide MS-275 µM HDACs 1, 2, 3, 8 
Cyclic tetrapeptide Depsipeptide 
Trapoxin A 
Apicidin 
CHAPs 
nM 
nM 
nM 
nM 
Class I 
Class I, IIa 
HDACs 1 and 3 
Class I 
Miscellaneous Depudecin µM Class I (Class II unknown) 
CHAP, cyclic-hydroxamic acid containing peptide. 
 
1.7.2 HDAC inhibitors as potential therapies for inflammatory and autoimmune disorders 
Recent studies suggest that HDAC inhibitors could be used as treatment therapies for 
inflammatory and autoimmune disorders such as lupus, rheumatoid arthritis, autoimmune encephalitis, 
multiple sclerosis, graft versus host disease, asthma and colitis (Table 1.5) (32,49). The first model of 
autoimmune disease in which HDAC inhibitors have shown beneficial effects is systemic lupus 
erythematosus (SLE). This disease is characterized by a skewed Th2 response, which promotes the 
production of pathogenic auto-antibodies by B cells. TSA was shown to shift the response of T cells 
from SLE patients from a Th2 to a Th1 phenotype (53). Moreover TSA and SAHA decreased the 
expression of pro-inflammatory cytokines and disease severity in MRL-lpr/lpr mice that 
spontaneously develop an autoimmune syndrome resembling SLE (53,54). Th2 responses are 
characterized by the secretion of IL-4, IL-5, IL-9 and IL-13 which promote the production of allergen-
specific IgE by B cells and the infiltration of inflammatory cells into the airways. Inhibition of HDAC 
by TSA in a mouse experimental model of asthma reduced airway hyper-responsiveness and allergic 
airway inflammation as well as pulmonary cytokines and IgE levels (55). 
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HDAC inhibitors have also been shown to impair Th1 responses. Indeed, HDAC inhibitors 
such as TSA, phenylbutyrate and FR901228 (depsipeptide) improved pathological scores in mouse 
and rat experimental models of arthritis biased for Th1 responses. The beneficial effects of HDAC 
inhibitors were associated with reduced expression of pro-inflammatory cytokine (among which TNF) 
and matrix-metalloproteinase-3 (MMP-3) and MMP-13 (responsible for matrix degradation), 
decreased synovial fibroblasts proliferation and reduced joint destruction (56-58). In mouse models of 
graft-versus-host disease (GVDH), SAHA and ITF2357 (two hydroxamate derivatives) decreased the 
production of Th1 cytokines (TNF, IL-1, IFNγ), increased the expression of indoleamine 2,3-
dioxygenase (IDO, a suppressor of DC function) in DCs and reduced gastrointestinal tract destruction 
(59,60). 
HDAC inhibitors were also studied as potential therapy for multiple sclerosis (MS), a 
demyelinating disease with a chronic inflammation of central nervous system white matter (61). In 
experimental autoimmune encephalomyelitis (EAE), a model of MS, TSA inhibited the activation of 
neuronal caspases and Th1 response of splenocytes. Of great interest, TSA also decreased spinal cord 
inflammation, demyelination, neuronal and axonal loss and ameliorated disability in relapsing phase 
of EAE (62). HDACs have also been recognized as promising therapeutic targets for many human 
brain or central nervous system diseases such as psychiatric (schizophrenia, drug addiction, anxiety) 
disorders, amyotrophic lateral sclerosis, Rubinstein-Taybi and Rett syndromes, Friedreich’s ataxia and 
Huntington’s disease (61,63). 
Considering the anti-inflammatory properties of HDAC inhibitors, one may speculate that 
these drugs interfere with innate immune responses. When we started our research project, very few 
studies had addressed that aspect. NaB was reported to inhibit IL-12 and to induce IL-10 production 
by human monocytes stimulated with Staphylococcus aureus (64). SAHA inhibited LPS-induced 
secretion of TNF, IL-1β and IFNγ by human PBMCs, and cytokine-induced nitric oxide by RAW 
264.7 cells. SAHA also reduced circulating levels of TNF, IL-1β, IL-6 and IFNγ in mouse injected 
with LPS (65). 
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Table 1.5. Beneficial effects of HDAC inhibitors therapy in experimental models of inflammatory and 
autoimmune diseases. 
Diseases Inhibitors Effects References 
Systemic lupus 
erythematosus 
TSA, SAHA Th1 activation 
↓  pro-inflammatory cytokines 
(53,54)  
Asthma TSA ↓  pulmonary pro-inflammatory cytokines and IgE (55) 
Arthritis TSA, NaB, 
depsipeptide 
↓  pro-inflammatory cytokines in joints 
↓ MMPs in joints 
(56-58) 
Graft-versus-host disease SAHA, ITF2357 ↓  pro-inflammatory cytokines 
↑  indoleamine 2,3-dioxygenase 
(59,60) 
Multiple sclerosis 
 
TSA ↓  activation of neuronal caspases 
↓  pro-Th1 cytokines mRNA in splenocytes 
(61) 
Colitis VPA, SAHA ↓  pro-inflammatory cytokines 
↑  apoptosis of lamina propria lymphocytes 
(66) 
 
1.8 Macrophage migration inhibitory factor 
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine found to play a 
crucial role in the control of innate immune responses, in the pathogenesis of sepsis, autoimmune 
diseases and cancers (67). The name MIF was coined in the early 1960s to describe the biological 
activity of a mediator released by activated lymphocytes inhibiting the migration of monocytes and 
exudate cells in vitro (68,69). MIF was rediscovered in the 90s as a factor released by anterior 
pituitary cells stimulated by LPS (70). MIF was thus proposed to be a linking factor of endocrine and 
immune systems. 
1.8.1 MIF gene 
Weiser and colleagues cloned a human MIF cDNA in the late 80s. They isolated the cDNA 
from a library established from a lectin-stimulated T-cell hybridoma (71). MIF is localized on 
chromosome 22 at position 22q11.2 (72). The MIF gene is less than 1 kb in length and is composed of 
three exons of 205, 173 and 183 bp separated by two introns of 189 and 95 bp. A single transcription 
start site, 95 bp upstream of the ATG, is situated in GC rich region lacking a TATA box. Yet, only one 
transcript of about 800 nucleotides could be identified by Northern blotting in several human tissues. 
The MIF gene is constitutively expressed in all organs, with high levels in the liver, kidney, brain and 
placenta and lower levels in the heart, skeletal muscle and pancreas (73). The MIF gene is structurally 
related to D-dopachrome tautomerase (DDT). The MIF and DDT genes are narrowly linked on human 
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chromosome 22 and mouse chromosome 10 (74), suggesting that they arose by duplication of an 
ancestral gene. 
1.8.2 Regulation of MIF gene expression 
Numerous DNA-binding sequences for transcription factors such as AP-1, NF-κB, E twenty-
six (Ets), GATA, Specificity protein 1 (Sp1) and cyclic AMP response element (CRE)-binding protein 
(CREB) are located in the human MIF gene promoter region. Two Sp1 and CRE sites in the vicinity of 
the human MIF gene transcriptional start site (designated proximal Sp1 and CRE or Sp1p and CREp, 
respectively, Figure 1.7A) were shown to bind Sp1 and CREB and to positively regulate MIF gene 
basal and microbial product-stimulated transcriptional activity in several cell lines (75). Chromatin 
immunoprecipitation (ChIP) assays confirmed the binding of Sp1 and CREB to the MIF proximal 
promoter in invo (75). 
The MIF gene lies within a CpG island. Interestingly, methylation of cytosine residues within 
CpG island is a major mechanism of epigenetic silencing. Yet, the MIF gene is not methylated in 
PBMCs and monocytic, epithelial and keratinocytic cell lines expressing different levels of MIF 
mRNA, suggesting that methylation of CpGs does not account for the differential expression of MIF 
mRNA (75). 
A B 
 
 
Figure 1.7. Structure of MIF promoter and MIF 3D view.  (A) Comparison of the proximal promoters of the 
human and mouse MIF genes. The proximal Sp1 and CRE sites regulating the constitutive human and mouse 
MIF promoter activity are highlighted in black (adapted from Roger et al., European Journal of Immunology, 
2007 (75)). (B) Crystal strucure at 2.6A of human MIF trimer showing solvent accessible channel (from Sun et 
al., Proceedings of the National Academy of Sciences of the United States of America, 1996 (76)). 
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1.8.3 MIF protein 
The MIF protein is a 12.5 kDa polypeptide composed of 115 amino acids. MIF is highly 
conserved amongst mammalian genomes, and MIF homologues are found in plants, nematodes, 
arthropods, protozoan and cyanobacteria (74). Three-dimensional structure revealed by electronic 
microscopy of MIF crystals exposed no structural similarity with other cytokines or hormones. MIF 
was found to crystallize as a homotrimer (Figure 1.7B), which is commonly admitted to be the active 
form. The homotrimer structure was determined to form a β-strand barrel with an inner solvent-
accessible channel whose surface is negatively charged (76,77). The channel is a potential binding site 
for small molecules like glutathione and dopachrome (76) or, by similarity with the enzyme 5-
carboxy-methyl-2-hydroxymuconate isomerase (CHMI) from E. coli, to be a catalytic site (77). 
MIF exerts tautomerase and thiol-protein oxydoreductase enzymatic activities. These activities 
were discovered because of the structure relationship between MIF and bacterial isomerase CHMI and 
DDT (78). Whether these enzymatic activities impact on MIF function in vivo is debatable. 
Nevertheless, ISO-1, a specific inhibitor of MIF tautomerase activity, was shown to block TNF release 
from LPS-stimulated macrophages and to increase mouse survival in models of septic shock (79). 
Overall, the molecular mechanisms linking the enzymatic and cytokine activities of MIF remain 
largely to be described. 
MIF is stored in secretory granules and is released upon stimulatory conditions. Given that 
MIF lacks the classical N-terminal glycosylation necessary for a classical ER/golgi export to plasma 
membrane, MIF secretion is mediated through a non-classical secretory pathway. The ABC 
transporter (80) and the Golgi-associated protein p115 (81) have been reported to exert this function. 
1.8.4 MIF function 
MIF activity was described in the late 60's as T-cell derived factor with the ability to inhibit 
the migration of macrophages and monocytes, correlating with delayed type hypersensitivity (68,69). 
Almost 30 years later, MIF was re-discovered as cytokine secreted in a hormone-like manner by 
pituitary cells during endotoxemia (70). Innate immune cells, especially macrophages, are an 
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important source of MIF. Macrophages stimulated with LPS rapidly secrete large quantities of 
preformed MIF. Additionally, organs containing large amounts of MIF are those commonly associated 
with a high macrophage content like the kidney, liver or brain (82). 
Different mechanisms by which cells respond to MIF stimulation have been identified. 
Extracellular MIF signals through a receptor composed of CD74 (i.e. the invariant chain of the MHC 
class II), the MIF binding receptor, and CD44, the signal transducing molecule of the MIF receptor 
complex (83,84). MIF also interacts with the chemokine receptors CXCR2 and CXCR4, thereby 
triggering leukocyte recruitment (85-87). Besides signaling through a membrane receptor, intracellular 
MIF modulates cell activity by interacting with JAB-1, a co-activator of AP-1 transcription factor 
(88), and p53 (89). 
Once released, MIF sustains inflammatory and immune responses, stimulating the production 
of inflammatory mediators by macrophages and providing a stimulus for the activation of T and B 
cells. Notably, MIF has been reported to up-regulate the expression of TLR4 in macrophages, 
allowing a quick response to Gram-negative bacteria (90). MIF also possesses the characteristic to be 
induced by physiological concentrations of glucocorticoids and to override the immunosuppressive 
and anti-inflammatory properties of glucocorticoids (91,92).  
MIF is considered as an integral component of the host antimicrobial alarm system and stress 
response that promotes pro-inflammatory functions of immune cells. Indeed, MIF is required for 
optimal host defenses against infection, as shown by its capacity to limit the growth of intracellular 
pathogens (93,94). Yet, excessive amounts of MIF produced during the acute phase of sepsis is 
deleterious, as shown by the fact that serum MIF levels are increased and correlate with outcome in 
patients with septic shock (95) and that neutralization of MIF activity improves outcome in animal 
sepsis models (96). Overall, MIF has been implicated in the pathogenesis of numerous inflammatory 
and auto-immune diseases, including sepsis, adult respiratory distress syndrome, glomerulonephritis, 
arthritis, colitis, pancreatitis, systemic lupus erythematosus, autoimmune uveïtis and sarcoidosis 
(Table 1.6) (67,97). 
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Table 1.6. MIF mechanisms of action and biological activities in pathologic conditions.  Adapted from Lue 
et al., Microbes and Infection, 2002 (98). 
 
1.8.5 MIF as a link between inflammation and cancer 
Recent studies strongly support an important role for MIF in the control of cell growth and 
tumorigenesis (Table 1.6). MIF stimulates cell proliferation, promotes cell survival and tumor-
associated neovascularization and inhibits antitumor natural killer (NK) and cytotoxic T-lymphocyte 
(CTL) responses. Moreover, MIF regulates tumor cell motility and invasion (summarized in (99)). 
MIF promotes tumorigenesis by suppression of p53 tumor suppressor activity (89) and by sustaining 
ERK1/2 activation and cell proliferation (100). MIF has also been shown to increase matrix 
metaloproteinases (MMPs) secretion, thus favouring tumor invasion. Furthermore CD44, a partner of 
the MIF receptor complex, has been demonstrated to promote the motility of tumor cells and 
metastasis, especially in breast cancer (101). Finally, human cancer tissues, such as prostate, breast, 
colon, brain, skin and lung-derived tumors, have been shown to overexpress MIF (99). 
Diseases/ pathologic 
conditions 
Associated MIF activity Mechanism(s) 
Septic Shock ↑ TNF, NO, IL-1, IL-6, IL-8 
↑ LPS signaling 
Up-regulation of TL4 
Binding of MIF to CD74 leading to ERK1/2 pathway 
activation 
Stress and glucocorticoid 
functions 
Counter-regulation of glucocorticoid 
action 
Counteracts steroid-induced upregulation of cytosolic 
IκBα 
Counteracts glucocorticoid-induced expression of 
MKP-1 
Inflammatory lung 
disorders 
↑ TNF, IL-8 
↑ arachidonic acid release 
Counter-regulation of glucocorticoid action 
↑ arachidonic acid release by MIF 
Rheumatoid arthritis ↑ MMP-1/MMP-3 in synovial 
fibroblasts 
↑ PLA-2 / COX-2 acitvity 
↑ TNF 
↑ PKC, Ap-1 and TK by MIF 
↑ MIF expression by 10
-10
-10
-12
M glucocorticoids in 
synoviocytes 
↑ PLA-2/COX-2 activity by MIF 
Cancer and 
tumorigenesis 
↓ p53 activity 
↓ Redox- and stress-induced 
apoptosis 
↑ PI3K/Akt survival pathway 
↑ Cell proliferation 
↑ Tumor invasion 
↑ Tumor cell metastasis and motility 
↓ p53 activity by MIF 
↑ of ERK1/2 activity By MIF 
↑ PI3K/Akt survival pathway by MIF 
MIF interacts with JAB1/CSN5 that interact with p53 
Modulation of JNK activity by MIF 
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1.9 Aim of the study 
When we initiated this project, several studies suggested that inhibitors of class I, II and IV 
HDAC (HDAC1-11) have anti-inflammatory activity. Yet, their influence on innate immune responses 
was largely uncharacterized. Thus, the overall aim of the study was to investigate the role of HDAC1-
11 inhibitors on host innate immune responses against bacterial and fungal infections. The three main 
objectives were to:  
- examine the influence of HDAC1-11 inhibitors on macrophage and dendritic cell functions 
in vitro and to investigate the molecular basis of the inhibition of innate immune responses 
by these compounds (chapter 2 and 3). 
- evaluate the impact of treatement with HDAC1-11 inhibitors on the susceptibility to 
bacterial and fungal sepsis in preclinical models of infection (chapter 2). 
- determine whether, and if so by which mechanisms, HDAC1-11 inhibitors interfere with the 
expression of MIF (chapter 4 and 5). 
 
Lately, we moved our attention towards the analysis of the influence of inhibitors of class III 
HDACs (i.e. sirtuins) on innate immune responses. This decision was motivated by the fact sirtuins 
and HDAC1-11 share numerous common substrates. In chapter 6 of this manuscript, we will first 
introduce sirtuins and sirtuin inhibitors and then present the preliminary results we obtained in vitro 
and in vivo. 
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2.1 Summary 
Inhibitors of class I, II and IV HDACs (i.e. HDAC1-11) are amongst the most promising anti-cancer 
drugs. Several studies have suggested that inhibitors of HDAC1-11 (thereafter called HDACi) have 
anti-inflammatory activity. Yet, their influence on innate immune responses remains largely 
uncharacterized. In the present study, we investigated the effects of HDACi (trichostatin A, valproate, 
and suberoylanilide hydroxamic acid) on host innate immune responses against TLR agonists and 
bacterial and fungal infections. 
Strikingly, genome-wide expression studies revealed that trichostatin A acts essentially as 
negative regulator of basal and microbial product-induced expression of critical immune receptors and 
antimicrobial products expressed by macrophages. These results were confirmed in a number of 
settings analysing the production of cytokines or the expression of co-stimulatory molecules by mouse 
and human macrophages, dendritic cells, splenocytes and whole blood treated with HDACi and 
stimulated with a broad range of bacterial and fungal products. At the molecular level, we demonstrate 
that HDACi impair pro-inflammatory cytokine expression without interfering with the activation of 
the NF-κB and MAP kinases signaling pathways. Most importantly, we identified a new molecular 
mechanism whereby HDACi stimulate the expression and the recruitment of the transcriptional 
repressor Mi-2β on the promoter of pro-inflammatory genes targeted by HDACi.  The relevance of the 
above findings was evaluated in vivo in experimental models of bacterial and fungal sepsis or toxic 
shock titrated to cause either mild or severe infections or shock. These experiments revealed that mice 
treated with valproate are more susceptible to non-severe bacterial and fungal infection, but are 
protected against toxic and septic shock. Altogether these data confirm the potent anti-inflammatory 
potential of HDACi in vivo. 
Overall, these studies ascribe HDAC a pivotal role in controlling the biologic functions of 
innate immune cells, and identified HDACi as powerfull anti-inflammatory drugs which may increase 
the susceptibility to infection in immunocompromised patients. Yet, the anti-inflammatory and 
immunosuppressive properties of HDACi may be beneficial as adjunctive therapy for septic shock. 
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Supplemental Tables S1, S2 and S3 are large datasets that cannot be inserted in this document for a 
matter of space. However they are available online at: 
http://bloodjournal.hematologylibrary.org/content/suppl/2010/10/07/blood-2010-05-
284711.DC1/Document1.pdf 
 
Table S4. Oligonucleotides used in this study 
 Forward (5’->3’) Reverse (5’->3’) 
For RT-PCR   
Actg1 CGCAAAGACCTGTATGCCAAT GGGCTGTGATCTCCTTCTGC 
Brg1 AAGGATGTGATGCTGCTGTG CTTTCCTCGCCTTCACTGTC 
Ccl2 GGATCAGAGATACTCATGAT GAGAAGATTACCTGAGTACA 
Ccl5 CTGCCGCGGGTACCATGAAG TACAGGGTCAGAATCAAG 
Ccl8 CGAGGGATTGAGAGGACGCT ATGAGAAAACACGCAGCCCA 
Ccl12 TTGGCTGGACCAGATGCG GGGACACTGGCTGCTTGTGA 
Cd14 CCCGACCCTCCAAGTTTTAG GCTTCAGCCCAGTGAAAGAC 
Cd36 TCCCTCACTGGAGGAAACTG TGTGATATCTGGCCTTGCTG 
Cd40 AGGTTTAAAGTCCCGGATGC CCTTTGGTTTCTTGACCACCT 
Cxcl10 GGATGGCTGTCCTAGCTCTGTAC TGGGCATGGCACATGGT 
Gapdh CTCATGACCACAGTCCATGC CACATTGGGGGTAGGAACAC 
Hprt GTTGGATACAGGCCAGACTTTGTTG GATTCAACTTGCGCTCATCTTAGGC 
Ifnb GCATTTGAAAGGTCAAAGGAA CCCTTTATAAGAAGTGTCCAGCA 
Ifna4 CCTGTGTGATGCAGGAACC TCACCTCCCAGGCACTGA 
Il6 AGCAGTAGCAGTTCCCCTGA AGTCCCTTTGGTCCAGTGTG 
Il12b GGAAGCACGGCAGCAGAATA AACTTGAGGGAGAAGTAGGAATGG 
iNos CTCTGACAGCCCAGAGTTCC GAAAGGGAGAGAGGGGAGG 
Irf7 CTGGAGCCATGGGTATGCA AAGCACAAGCCGAGACTGCT 
Irf8 GATCAAGGAACCTTCTGTGG GAAGCTGATGACCATCTGGG 
Md2 CAACTCCTCCGATGCAATTA GGCACAGAACTTCCTTACGC 
Mi2b CAGCAAACAGCGTTTCATGT AGCCAGCAGCCAGTAATCAT 
Tlr1 CAATGTGGAAACAACGTGGA TGTAACTTTGGGGGAAGCTG 
Tlr2 AAGAGGAAGCCCAAGAAAGC CGATGGAATCGATGATGTTG 
Tlr3 CACAGGCTGAGCAGTTTGAA TTTCGGCTTCTTTTGATGCT 
Tlr4 ACCTGGCTGGTTTACACGTC CTGCCAGAGACATTGCAGAA 
Tlr5 AAGTTCCGGGGAATCTGTTT GCATAGCCTGAGCCTGTTTC 
Tlr6 CAGAACTCACCAGAGGTCCAA CGAGTATAGCGCCTCCTTTG 
Tlr7 AATCCACAGGCTCACCCATA CAGGTACCAAGGGATGTCCT 
Tlr8 GACATGGCCCCTAATTTCCT GACCCAGAAGTCCTCATGGA 
Tlr9 ACTGAGCACCCCTGCTTCTA AGATTAGTCAGCGGCAGGAA 
Tnf CCAGGCGGTGCCTATGTCT GGCCATTTGGGAACTTCTCAT 
   
For ChIP   
Tnf CAACTTTCCAAACCCTCTGC CTGGCTAGTCCCTTGCTGTC 
Il6 AGGGCTAGCCTCAAGGATGA AACCCACAATGCTGGCTCT 
Il12b TCTGCCTCCTTCCTTTTTCC AGCTGCCTGGTCTGATGTG 
   
For siRNA   
Control AGGUAGUGUAAUCGCCUUGdTdT  
Mi2b GAAACCUCGAGACCCUAAAdTdT  
Brg1 GGUAGAGUAUGUCAUCAAAdTdT  
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Figure S1. Trichostatin A inhibits the expression of LPS-induced IFN-β-dependent genes in 
macrophages. Bone marrow derived macrophages were pre-incubated for 1 h with or without TSA (100 nM) 
prior to exposure for 4 h to LPS (100 ng/mL). The expression of LPS-induced (fold-change > 2 versus medium) 
IFN-β-dependent genes (Thomas et al, J. Biol. Chem. 2006; 281:31119-31130) was analyzed with Agilent 
Mouse Oligo Microarray Kit (V2). 
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3.1 Abstract 
Histone deacetylases (HDACs) control gene expression by deacetylating histones and non-histone 
proteins. HDAC inhibitors (HDACi) are powerful anticancer drugs that exert anti-inflammatory and 
immunomodulatory activities. We recently reported a proof of concept study demonstrating that 
HDACi increase susceptibility to bacterial infections in vivo. Yet, still little is known about the effects 
of HDACi on host antimicrobial innate immune defences. Here we show that HDACi belonging to 
different chemical classes inhibit at multiple levels the response of macrophages to bacterial infection. 
HDACi reduce the phagocytosis and the killing of Escherichia coli and Staphylococcus aureus by 
macrophages. In line with these findings, HDACi decrease the expression of phagocytic receptors and 
inhibit bacteria-induced production of reactive oxygen and nitrogen species by macrophages. 
Consistently, HDACi impair the expression of NADPH oxidase subunits and inducible nitric oxide 
synthase. These data indicate that HDACi have a strong impact on critical antimicrobial defence 
mechanisms in macrophages. 
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3.2 Introduction 
 The innate immune system plays a crucial role in host defences against invasive 
microorganisms. Professional phagocytes are key sentinel cells of the innate immune system. 
Pathogen recognition relies on the capacity of phagocytes to sense microbial molecular motifs (e.g. 
lipopolysaccharide, peptidoglycan, lipopeptides, mannans, glucans, flagellin and nucleic acids) via 
pattern-recognition receptors comprising Toll-like receptors (TLRs), nucleotide-binding 
oligomerization domain-like receptors (NLRs), retinoic acid-inducible gene I (RIG-I) like receptors 
(RLRs), C-type lectin receptors (CLRs) and scavenger receptors (1). The engagement of phagocytic 
receptors, either through a direct interaction with microbial motifs or through the recognition of 
opsonized infectious agents, stimulates the engulfment and the delivery of the pathogen to the 
phagosome. Phagosome maturation by fission and fusion with endosomes and lysosomes generates the 
phagolysosome which provides a powerful microbicidal microenvironment usually resulting in 
efficient microbial killing (2, 3). The release of pro-inflammatory cytokines during the course of an 
infection stimulates the production of powerful phagocyte activating molecules like interferon γ 
(IFNγ). 
 Reversible acetylation of the ε amino groups of lysine residues from histones and non-histone 
proteins (such as α-tubulin, steroid receptors, HSP90 and regulators of nuclear import and 
transcription) is controlled by histone acetyltransferases and histone deacetylases (HDACs). 
Generally, acetylated histones are associated with active gene transcription, whereas deacetylated 
histones are associated with transcription repression (4-6). The eighteen mammal HDACs have been 
classified into class I (HDAC1-3 and 8), class IIa (HDAC4, 5, 7 and 9), class IIb (HDAC6 and 10), 
class III (SIRT1-7) and class IV (HDAC11) HDACs (4, 7). Small molecule inhibitors of class I, II and 
IV HDACs were originally identified for their potential to induce cellular differentiation, growth arrest 
and apoptosis of transformed cells. HDACi targeting class I and II HDACs have been reported to 
counteract cancer development by reducing tumor angiogenesis, metastasis and invasion and 
antitumor immunity (4-6).  
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 Beside their anti-cancer properties, HDACi exert immunomodulatory activities that have been 
exploited for the treatment of inflammatory and auto-immune disease (8). Recently, we reported that 
HDACi interfere with the response of innate immune cells stimulated with TLR agonists and increase 
the mortality of mice to microbial sepsis (9). Yet, whether HDACi impair the phagocytosis and the 
killing of bacteria by phagocytes remains unknown. To more deeply characterize the influence of 
HDACi on innate immune responses, we investigated whether HDACi have an impact on key 
antibacterial defence mechanisms of macrophages. We report that HDACi reduce the expression of 
phagocytic and opsonophagocytic receptors and inhibit the phagocytosis of Escherichia coli (E. coli) 
and Staphylococcus aureus (S. aureus), two of the most common infectious agents, by macrophages. 
Moreover, HDACi impair the generation of reactive oxygen and nitrogen species by macrophages 
infected with bacteria, resulting in a marked reduction of bacterial killing. 
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3.3 Material and Methods 
3.3.1 Cells and reagents 
 Animal procedures were approved by the Office Vétérinaire du Canton de Vaud 
(authorizations n° 876.6) and performed according to institution guidelines for animal experiments. 
Eight to ten-week-old female BALB/c mice were purchased from Charles River Laboratories 
(L'Arbresle, France). Mouse bone marrow-derived macrophages (BMDMs) and thioglycollate-elicited 
macrophages were obtained as previously described (10, 11). RAW 264.7 macrophages were cultured 
in RPMI 1640 medium containing 2 mM glutamine and 10% FCS (12). E. coli O18:K1:H7 (E. coli) 
and S. aureus AW7 (S. aureus) are clinical isolates obtained from septic patients hospitalized at the 
Centre Hospitalier Universitaire Vaudois (Lausanne, Switzerland). Trichostatin A (TSA) and valproic 
acid (VPA) were purchased from Sigma-Aldrich (St Louis, MO), Salmonella minnesota Ultra Pure 
LPS from List Biologicals Laboratories (Campbell, CA) and IFNγ from R&D Systems (Abingdon, 
UK). The concentrations of TSA (dissolved in ethanol) and VPA (dissolved in PBS) used in this study 
were selected based on previous publications (13-18) and did not affect the viability (Trypan blue 
staining and MTT Cell Proliferation and Viability Assay) of BMDMs (> 85 % cell recovery after 18 h 
of culture with 20-40 nM TSA and 1-2 mM VPA with or without bacteria. n = 6-9 determinations. P > 
0.5 for all conditions). Ethanol and PBS vehicle controls were performed in each experiment. For 
simplicity only one set of data is presented in each figure. 
3.3.2 Assay for bacterial uptake and bacterial killing 
 E. coli and S. aureus were grown overnight at 37°C in tryptic soy broth (BD Biosciences, 
Erembodegem, Belgium), washed in PBS and adjusted to 107 CFU/ml in RPMI medium containing 
10% FCS. BMDMs (4 x 105 cells in 24-well cell-culture plates, Costar, Cambridge, MA) were treated 
with TSA or VPA for 18 h. Medium was changed and cells were incubated for 1 h with bacteria at a 
multiplicity of infection of 20 bacteria per macrophage. Non-adherent bacteria were removed by 
washing with PBS. Extracellular bacteria were killed by a 30-min exposure to either 100 mg/ml of 
gentamicin (E. coli) or to 10 mg/ml of lysostaphin (S. aureus). BMDMs were washed and lysed. Serial 
dilutions of cell lysates were plated on agar plates and colonies enumerated to calculate the number of 
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phagocytosed bacteria. In parallel wells, BMDMs were treated as above except that, after 30 min of 
incubation with antibiotics, cells were washed and incubated for a further 24 h in culture medium 
containing 20 mg/ml gentamicin or 10 mg/ml lysostaphin. Bacteria were enumerated and results 
expressed as percent changes in bacterial counts using the following formula: (count after 24 h / count 
after 1 h) x 100. Of note, neither TSA nor VPA at the concentrations used in the above assays were 
toxic for bacteria. 
3.3.3 RNA analysis by quantitative real-time polymerase chain reaction 
 RNA was isolated using the RNeasy kit (Qiagen, Hombrechtikon, Switzerland). Reverse 
transcription was carried out using the ImProm II RT System kit (Promega, Dübendorf, Switzerland). 
Quantitative real-time PCR was performed with a 7500 Fast Real-Time PCR System using the Power 
SYBR Green PCR Master Mix (Applied Biosystems, Rotkreuz, Switzerland) and primer pairs 
(Supplementary Table 1) as previously described (19). Samples were tested in triplicates. For each 
measurement, a standard made of successive dilutions of a reference cDNA was processed in parallel. 
The relative expression levels of NADPH oxidase subunits and iNOS were reported to the relative 
expression of Gapdh and expressed in arbitrary units (A.U.). The expression of phagocytic receptors 
and TLRs was calculated with the Comparative Ct Method (ΔΔCt method). The expression of the 
target gene was first normalized to the endogenous control (Gapdh) and then to that of a calibrator (i.e. 
data obtained from cells cultured with vehicle set at 1). Importantly, the Ct values of Gapdh were not 
affected by TSA or VPA (19.24±0.13, 19.10±0.03, 19.30±0.48, 19.21±0.06 and 19.10±0.15 in 
BMDMs cultured for 18 hours with medium, 20 nM TSA, 40 nM TSA, 1 mM VPA and 2 mM VPA, 
respectively. n = 6 determinations. P > 0.05 for all conditions compared to cells cultured in medium). 
In selected experiments, results were validated using Hprt as an endogenous control. 
3.3.4 Flow cytometric analysis 
 BMDMs cultured for 18 h with TSA (40 nM) and VPA (2 mM) were incubated 30 min at 4°C 
in PBS containing 5% FCS, 5 mM EDTA, 2.4G2 mAb and mAbs specific for macrophage scavenger 
receptor 1 (Msr1/CD204), CD11c, CD14 and MHC-II (20). Acquisition and analysis were performed 
using a FACSCaliburTM (BD Biosciences) and FlowJo 8.5.3 software (FlowJow, Ashland, OR). 
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3.3.5 Analysis of oxidative burst using the dichlorofluorescein diacetate fluorescence assay 
BMDMs (4 x 105 cells in 24-well cell-culture plates) were cultured as previously described 
(21) and incubated for 18 h with TSA and VPA. Dichlorofluorescein diacetate (DCFDA) (20 mM, 
Sigma-Aldrich) was added to the cultures followed 15 min later by bacteria (5 x 108 CFU/ml). After 
30 min, cell fluorescence was measured by flow cytometry. 
3.3.6 Western blot analysis 
 Cell-lysates were electrophoresed through polyacrylamide gels and transferred onto 
nitrocellulose membranes as previously described (12). Membranes were incubated with antibodies 
directed against iNOS (BD Biosciences), p47phox (Santa Cruz, Santa Cruz, CA) and tubulin (Sigma). 
After washing, membranes were incubated with HRP-conjugated secondary antibody (Pierce). Signals 
were revealed using the ECL Western blotting Analysis System (GE Healthcare). 
3.3.7 Nitrite/nitrate measurements 
 BMDMs (105 cells in 96-well cell-culture plates) were pre-incubated for 1 h with TSA and 
VPA and stimulated with LPS (100 ng/ml), IFNγ (100 U/ml), E. coli and S. aureus (108 CFU/ml). Cell 
culture supernatants were collected after 24 h. The concentrations of nitrite/nitrate were measured 
using the Griess reagent. 
3.3.8 Statistics 
 Statistical analyses were performed using PRISM (GraphPad Software, La Jolla, CA). 
Comparisons between the different groups were performed by analysis of variance using ANOVA and 
appropriate post-hoc analyses. P values are two-sided and values of less than 0.05 were considered to 
indicate statistical significance. 
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3.4 Results 
3.4.1 HDACi inhibit bacterial phagocytosis by macrophages 
 We recently reported that HDACi impair host defenses to bacterial infection in vivo (9). 
Whether HDACi impact on the phagocytosis and the killing of bacteria is currently unknown. To fill 
in this gap, we first analyzed the phagocytosis of Gram-negative (E. coli) and Gram-positive (S. 
aureus) bacteria by bone marrow-derived macrophages (BMDMs) pretreated with two chemically 
unrelated HDACi: trichostatin A (TSA), a hydroxamate widely used as a prototypical broad spectrum 
HDACi, and valproic acid (VPA), a clinically relevant short fatty acid. The dose and duration of 
treatment with TSA and VPA were in the range of those used in cancer preclinical studies or measured 
in patients enrolled in cancer clinical trials (VPA) (see for example (13-18)). Phagocytosis was 
evaluated after 1 h of contact between bacteria and macrophages. As shown in Figure 3.1, HDACi 
dose dependently reduced the number of E. coli (2 to 4-fold; P < 0.05) and S. aureus (1.5 to 2-fold; P 
< 0.05) phagocytosed by BMDMs.  
Figure 3.1. Histone deacetylase 
inhibitors impair the phagocytosis of 
E. coli (A) and S. aureus (B). 
BMDMs were incubated for 18 h with 
increasing concentrations of TSA and 
VPA before the addition of 107 CFU of 
E. coli or 1.5 x 107 CFU of S. aureus. 
The number of bacteria ingested by 
BMDMs was determined 1 h later. 
Data are means ± SD of quadruplicate 
samples from one experiment 
representative of two to three 
experiments. *, 0.05 < P < 0.005; **, P 
< 0.005. 
 
 
3.4.2 HDACi impair the expression of phagocytic receptors 
 Macrophages express phagocytic scavenger receptors, including macrophage scavenger 
receptor 1 (Msr1/SR-AI/CD204), CD14 and CD36 and C-type lectins such as Dectin-1 (encoded by 
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Cle7a) which mediate the recognition of microbial ligands expressed at the surface of pathogens and 
initiate phagocytosis. Macrophages also express opsonic phagocytic receptors of the integrin family 
(integrinαX/Itgax/CD11c, integrinß2/Itgb2/CD18, integrinα5/Itga5/CD49e) that facilitate the uptake of 
microorganisms coated with opsonins like the mannose binding lectin, complement sub-components, 
growth arrest specific 6, ficolins and pentraxins (2, 22). TSA and VPA reduced 2-10-fold Msr1, 
CD14, Dectin-1 and Itgax mRNA levels in BMDMs (Figure 3.2A). TSA inhibited Itgb2 expression 
more efficiently than VPA (2.4-fold with 40 nM TSA versus 1.4-fold with 2 mM VPA), whereas 
HDACi did not affect CD36, Itga5 and Itga6 expression. Flow cytometry analyses confirmed that TSA 
and VPA inhibited the expression of Msr1, CD11c and CD14 by BMDMs (Figure 3.2B). As a control 
of non-specific broad inhibitory effects of HDACi, MHC-II expression was not affected by HDACi. 
Altogether, these data suggest that reduced expression of phagocytic receptors may contribute to 
impair the phagocytosis of E. coli and S. aureus in macrophages treated with HDACi. 
Figure 3.2. Histone deacetylase inhibitors 
inhibit the expression of phagocytic and Toll-
like receptors. (A) Real-time PCR analysis of 
Msr1, CD14, CD36, Clec7a, Itgax, Itgb2, Itga5 
and Itga6 mRNA expression in BMDMs 
incubated for 8 h with increasing concentrations 
of TSA and VPA. Data are means ± SD of 
triplicate samples from one experiment and are 
representative of two independent experiments. 
(B) Flow cytometry analysis of Msr1, CD14, 
CD11c and MHC-II expression by BMDMs 
incubated for 18 h with medium (grey area), 
TSA (dashed line) and VPA (solid line). 
Results are representative of two independent 
experiments. (C) Real-time PCR analysis of 
TLRs in BMDMs incubated for 8 h with 
increasing concentrations of TSA and VPA. 
Data are means ± SD of triplicate samples from 
one experiment and are representative of two 
independent experiments. A.U.: arbitrary units. 
*, 0.05 < P < 0.005; **, P < 0.005. 
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Figure 3.2 (continued). Histone 
deacetylase inhibitors inhibit the 
expression of phagocytic and Toll-
like receptors.  
 
 
3.4.3 HDACi inhibit bacterial killing 
 TLRs play a crucial role in the sensing of invasive microorganisms and in transmitting signals 
involved in the maturation of phagosomes (23). Interestingly, we observed that HDACi strongly 
reduced baseline expression of TLR1-7 and TLR9 in BMDMs (Figure 3.2C). Pathogen delivery to 
phagolysosomes usually results in effective microbial killing (2, 24). In agreement, less than 5% of E. 
coli and 25% of S. aureus phagocytosed by BMDMs were recovered 24 h later in macrophages (P < 
0.001) (Figure 3.3). TSA and VPA reduced 5-fold and 3-fold E. coli and S. aureus killing respectively 
(i.e. increasing bacteria recovery to 25% and 75% of the ingested inoculum; P < 0.05). Thus, HDACi 
inhibit both the phagocytosis and the killing of bacteria by macrophages, in agreement with the 
observation that HDACi increased the susceptibility of mice to microbial infection (9). 
Figure 3.3. Histone deacetylase inhibitors 
impair the killing of E. coli and S. aureus. 
BMDMs were cultured for 18 h with 
increasing concentrations of TSA and VPA 
before the addition of 107 CFU of E. coli or 
1.5 x 107 CFU of S. aureus. The number of 
bacteria recovered from macrophages after 
24 h was divided by to the number of 
bacteria recovered after 1h and expressed in 
percentage using the formula (i.e. (count 
after 24 h / count after 1 h) x 100). Data are 
means ± SD of quadruplicate samples from 
one experiment representative of two to 
three experiments. *, 0.05 < P < 0.005; **, 
P < 0.005. 
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3.4.4 HDACi interfere with the generation of reactive oxygen species 
 In response to microbial challenge, macrophages produce highly toxic reactive oxygen species 
(ROS), which contribute to pathogen destruction (25). The generation of ROS in BMDMs was 
analyzed by flow cytometry using the cell permeable non-fluorescent dye DCFDA that is transformed 
upon oxidation into the highly fluorescent DCF. E. coli and S. aureus strongly increased DCF 
fluorescence in BMDMs, which was inhibited 2- to 3-fold by TSA or VPA (Figure 3.4A and 3.4B). 
HDACi also inhibited the production of ROS in BMDMs stimulated with phorbol myristate acetate (> 
10-fold reduction, data not shown) indicating that HDACi inhibit the oxidative burst induced by 
microbial and non-microbial stimuli. 
Figure 3.4. Histone deacetylase 
inhibitors interfere with the 
generation of reactive oxygen species. 
BMDMs were incubated with TSA (40 
nM) and VPA (2 mM) and exposed to E. 
coli or S. aureus as described in 
Material and Methods. (A) The 
generation of ROS was quantified by 
flow cytometry by measuring 
dichlorofluorescein (DCF) diacetate 
oxidation into fluorescent DCF. (B) Data 
are means ± SD of two independent 
determinations. P = 0.03 and 0.08 for E. 
coli and S. aureus versus control. *,  P = 
0.05; *, 0.05 < P < 0.005 versus E. coli 
and S. aureus treated cells.  
 
 
 
 
 In macrophages, ROS are generated during the respiratory burst through the action of the 
phagocytic NADPH oxidase, an enzymatic complex composed of two membrane associated subunits, 
gp91phox/NOX2 and p22phox, three cytosolic subunits, p47phox, p40phox and p67phox, and the Rac2 
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regulatory subunit (26, 27). Cytokines, particularly IFNγ, and microbial products released during the 
course of an infection prime and amplify macrophage respiratory burst through the induction of 
NADPH oxidase subunits (21). Real-time PCR and Western blot analyses revealed that TSA and VPA 
dose-dependently inhibited baseline expression of NADPH oxidase subunits and potently inhibited the 
up-regulation of the catalytic gp91phox and regulatory p47phox subunits in LPS+IFNγ-stimulated 
macrophages (Figure 3.5). Altogether, these data provide compiling evidence that HDACi inhibit 
ROS production in macrophages. 
 
Figure 3.5. Histone deacetylase inhibitors inhibit NADPH oxidase subunits expression. (A) Real-time PCR 
analysis of gp91, p22, p47, p67, p40 and Rac2 mRNA expression in BMDMs cultured for 8 h with TSA and 
VPA. Results are expressed as the ratio of the gene of interest to that of Gapdh. Real-time PCR (B) and Western 
blot (C) analyses of gp91 and p47 expression in BMDMs cultured for 1 h with TSA and VPA and then 
stimulated for 6 h with LPS+IFNγ (100 ng/ml and 100 U/ml). Data are means ± SD of triplicate samples from 
one experiment and are representative of two independent experiments (A, B). *, P < 0.005 versus control (A) 
and LPS+IFNγ (B). A.U.: arbitrary units. 
 
3.4.5 HDACi inhibit nitric oxide production and iNos gene expression 
 Nitric oxide (NO) is produced during the nitrosative burst by iNOS and represents an 
important antimicrobial effector mechanism (25, 27). TSA and VPA dose-dependently inhibited the 
production of NO by BMDMs stimulated with LPS+IFNγ (50-80% reduction; P < 0.05), in line with 
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previous work showing that HDACi inhibit cytokine-induced NO release (28, 29). More relevant for 
microbial infection, TSA and to a lesser extend VPA inhibited NO production induced by E. coli and 
S. aureus (50-60% reduction using 20 and 40 nM TSA and 30-35% reduction using 2 mM VPA; P < 
0.05) (Figure 3.6A). In agreement with these findings, real-time PCR and Western blot analyses 
demonstrated that TSA and VPA inhibited iNOS mRNA and protein expression in BMDMs (Figure 
6B and 6C). Similar results were obtained using thioglycollate-elicited peritoneal and RAW 264.7 
macrophages (data not shown). Taken together, these results suggest that HDACi impair NO 
production by BMDMs in response to bacterial challenge by interfering with iNOS expression. 
 
Figure 3.6. Histone deacetylase 
inhibitors impair nitric oxide 
production and iNos gene expression. 
BMDMs were cultured for 1 h with TSA 
and VPA and then stimulated with 
LPS+IFNγ (100 ng/ml and 100 U/ml), E. 
coli and S. aureus (108 CFU/ml) for 24 h 
(A) or 8 h (B-C). (A) Nitrite/nitrate 
concentration in cell culture supernatants 
was measured using the Griess reagent. 
Data are means ± SD of triplicate 
samples from one experiment and are 
representative of four independent 
experiments. Real-time PCR (B) and 
Western blot (C) analyses of iNOS 
expression. Results are expressed as the 
ratio of iNos mRNA levels to that of 
Gapdh. Data are means ± SD of 
triplicate samples from one experiment 
and are representative of three 
independent experiments. A.U.: arbitrary 
units. *, 0.05 < P < 0.005; **, P < 0.005. 
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3.5 Discussion 
 In the present study, we report for the first time that HDACi inhibit the phagocytosis and the 
killing of bacteria, the expression of phagocytic receptors and the generation of oxidative and 
nitrosative bursts induced by bacteria in macrophages. These data extend our previous work 
demonstrating that HDACi interfere with cytokine production by macrophages and impair host 
defenses to bacterial infection (9). 
 The inhibition of E. coli and S. aureus phagocytosis by HDACi was associated with a reduced 
expression of phagocytic receptors, among which Msr1 (scavenger receptor A1). Mrs1 binds a wide 
range of microbial ligands and mediates non-opsonic phagocytosis of E. coli and S. aureus (30). 
Moreover, Msr1-/- mice are more susceptible than wild-type mice to S. aureus infection (31). Thus, 
HDACi-mediated inhibition of Msr1 expression may well contribute to impair bacterial phagocytosis, 
although HDACi may target other phagocytic receptors such as the mannose receptor, MARCO or 
CD14. Of note, HDACi decreased Dectin-1 expression in BMDMs. Considering that Dectin-1 is a 
major receptor involved in the recognition of ß-glucan, we speculate that HDACi may affect the 
phagocytosis of yeast. In line with this hypothesis, we observed that VPA increases mortality of mice 
infected with Candida albicans (9). 
 The αx and ß2 integrin subunits contribute to the structure of complement receptor (CR) 3 and 
CR4 which mediate the recognition of opsonized microorganisms by phagocytes. ß2 integrins play an 
important role in anti-microbial defences as suggested by the observation that patient with leukocyte 
adhesion deficiency type I (LADI) syndrome (i.e. patients deficient in functional ß2 integrin) have 
defects in phagocytosis and are prone to bacterial infections (32). Altogether, inhibition of the 
expression of αx and ß2 integrins and scavenger and lectin receptors by HDACi support the contention 
that HDACi interfere with bacterial opsonic and non-opsonic phagocytosis. 
 HDACi powerfully inhibited the killing of E. coli and S. aureus by macrophages. This 
observation is congruent with the fact that VPA treatment increased the proportion and the magnitude 
of bloodstream infections in mice infected with Klebsiella pneumoniae (9). Reactive oxygen and 
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nitrogen species are among the most deleterious components produced by phagocytes and implicated 
in the destruction of microorganisms (2, 24). Deficiency in members of the NADPH oxidase complex 
or in iNOS, which control the generation of superoxide (O2-°) and nitric oxide (NO°) radicals, impair 
the killing of E. coli and S. aureus by innate immune cells and compromise mouse survival (33-36). 
Moreover, germ-line mutation in one of the components of NADPH oxidase complex results in 
chronic granulomatous disease characterized by recurrent bacterial and fungal infections and reduced 
life expectancy (25). Inhibition of NADPH oxidase subunit and iNOS expression and of reactive 
oxygen and nitrogen species generation by HDACi likely represents an effective mechanism by which 
these drugs impair the killing of bacteria. 
 In agreement with the notion that phagocytosis is coupled with a proinflammatory cytokine 
response and with the observation that HDACi inhibit TLR expression, HDACi strongly impaired the 
secretion of cytokines and chemokines (TNF, IL-6, IL-12p40 and MIP-2α, data not shown) by 
macrophages infected with E. coli and S. aureus. These data expand on recent studies showing that 
HDACi inhibit cytokine production induced by cytokines and purified microbial products in innate 
immune cells (14, 15, 28, 37, 38). Considering that proinflammatory mediators released during the 
course of an infection coordinate the development of innate and adaptive immunity, one may 
anticipate that HDACi interfere with the generation of pathogen-specific adaptive immune response. 
 HDACi have been reported to interfere with signaling pathways controlling the expression of 
genes particularly relevant for the present study. Indeed, HDACi down-regulate the expression of 
PU.1 transcription factor (37, 39), which regulates constitutive expression of HDACi-target genes 
encoding for integrins, scavenger receptors, TLR4, CD14 and p40, p47 and p67 NADPH oxidase sub-
units (20, 40). Moreover, HDACi have been reported to interfere with the activation of mitogen 
activated protein kinases (MAPKs), NF-κB and AP-1 which control inflammatory and antimicrobial 
host responses (15, 41). Albeit less well characterized, HDACi also impair gene expression through 
chromatin modifications or aceytlation-dependent recruitment of transcriptional repressors. For 
example, TSA inhibits the expression of the proinflammatory cytokine macrophage migration 
inhibitory factor (MIF) through a local deacetylation of MIF-promoter associated histones impairing 
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the recruitment of the basal transcriptional machinery (42, 43). Finally, we have recently shown that 
TSA inhibits macrophage response to LPS stimulation by inducing the expression of Mi-2β and the 
activity of the Mi-2/NuRD transcriptional repressor complex (9). 
 HDACi have been used to treat inflammatory diseases in mouse models (8). Abundant 
preclinical and clinical studies indicate that interfering with critical mediators of innate or adaptive 
immunity increases the risk of infections. Thus, one may question whether HDACi might affect 
natural host defenses in patients, as could be anticipated from the powerful immunomodulatory and 
anti-inflammatory activities of HDACi in vivo (8) and the increased susceptibility to bacterial and 
fungal infections of mice treated with HDACi (9). Patients treated with HDACi (SAHA, MS-275, 
valproate and ITF2357) in phase I and II clinical trials have developed episodes of severe infection 
even in the absence of treatment-induced neutropenia (44-49), suggesting the need of monitoring the 
immune status and susceptibility to infection of patients treated with HDACi, especially 
immunosuppressed cancer patients (4-6, 50). 
 In summary, the present study demonstrates that HDACi impair the capacity of macrophages 
to ingest and destroy Gram-positive and Gram-negative bacteria. The fact that HDACi impede the 
expression of phagocytic receptors, the generation of oxygen and nitrogen reactive species and the 
release of proinflammatory cytokines provide a plausible mechanism whereby HDACi negatively 
impact on critical antimicrobial functions of innate immune cells and increase the susceptibility of 
mice to bacterial and fungal infection (9). 
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Supplementary Table 1. Oligonucleotides used for real-time PCR. 
 
Gene Forward (5’->3’) Reverse (5’->3’) 
Cd14 CCCGACCCTCCAAGTTTTAG GCTTCAGCCCAGTGAAAGAC 
Cd36 TCCCTCACTGGAGGAAACTG TGTGATATCTGGCCTTGCTG 
Gapdh CTCATGACCACAGTCCATGC CACATTGGGGGTAGGAACAC 
Hprt GTTGGATACAGGCCAGACTTTGTTG GATTCAACTTGCGCTCATCTTAGGC 
iNos (Nos2) CTCTGACAGCCCAGAGTTCC GAAAGGGAGAGAGGGGAGG 
Itgax (Cd11c) CTCCTGAGTGAGGCTGAAATCA TTATACATCTCCAGCACTGTCTTCGT 
Itgb2 (Cd18) ACAATCTTGCCGCAGAGC AAGTTGGGGCCACCTTTACT 
Itga5 (Cd49e ) CTCGGCTTCTTCAAACGTTC AAGAAGAGCTTCTCCCCAGC 
Msr1 (Cd204) AGTGTAGGCGGATCAACCC TCACTTCATTCAGCCATATTGG 
p22phox (Cyba) AGGGGTCCACCATGGAGCGA GCTCAATGGGAGTCCACTGC 
p40phox (Ncf4) CCGCCGCTATCGCCAGTTCTAC CCGGCAGGCTCAGGAGGTTCT 
p47phox (Ncf1) CTATCTGGAGCCCCTTGACA ACAGGGACATCTCGTCCTCTT 
p67phox (Ncf2) CCAGAAGACCTGGAATTTGTG AAATGCCAACTTTCCCTTTACA 
gp91phox (Cybb) CCAACTGGGATAACGAGTTCA GAGAGTTTCAGCCAAGGCTTC 
Rac2 GACACCATCGAGAAGCTGAAG GTGAGTGCAGAACATTCCAAGT 
Tlr1 CAATGTGGAAACAACGTGGA TGTAACTTTGGGGGAAGCTG 
Tlr2 AAGAGGAAGCCCAAGAAAGC CGATGGAATCGATGATGTTG 
Tlr3 CACAGGCTGAGCAGTTTGAA TTTCGGCTTCTTTTGATGCT 
Tlr4 ACCTGGCTGGTTTACACGTC CTGCCAGAGACATTGCAGAA 
Tlr6 CAGAACTCACCAGAGGTCCAA CGAGTATAGCGCCTCCTTTG 
Tlr7 AATCCACAGGCTCACCCATA CAGGTACCAAGGGATGTCCT 
Tlr8 GACATGGCCCCTAATTTCCT GACCCAGAAGTCCTCATGGA 
Tlr9 ACTGAGCACCCCTGCTTCTA AGATTAGTCAGCGGCAGGAA 
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4 HISTONE DEACETYLASE INHIBITORS REPRESS MACROPHAGE MIGRATION 
INHIBITORY FACTOR (MIF) EXPRESSION BY TARGETING MIF GENE 
TRANSCRIPTION THROUGH A LOCAL CHROMATIN DEACETYLATION 
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Thierry Calandra, and Thierry Roger 
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4.1 Summary 
 Macrophage migration inhibitory factor (MIF) is an important player of inflammation and 
tumorigenesis. Moreover, MIF levels correlate with tumor aggressiveness and metastatic potential. 
Given that inhibitors of class I, II and IV HDACs (HDACi) are potent antitumor agents with anti-
inflammatory activity, we tested the hypothesis that MIF represents a target of HDACi. Confirming 
our hypothesis, PCR analysis of MIF gene expression revealed that HDACi of various chemical 
classes (trichostatin A, valproate and suberoylanilide hydroxamic acid) strongly inhibit MIF gene 
expression in a broad range of cell lines including myeloid cells, epithelial cells, keratinocytes and 
melanoma. Moreover MIF protein expression was deacreased in human whole blood and in the 
circulation of mice treated with trichostatin A. Nuclear run on coupled to transient transfection with 
MIF promoter reporter constructs and transduction with MIF expressing adenovirus revealed that 
trichostatin A inhibits endogenous, but not episomal, MIF gene transcription. These results highlighted 
the importance of the endogenous chromatin landscape in HDACi-mediated MIF inhibition. 
Interestingly, chromatin immunoprecipitation (ChIP) studies showed that trichostatin A induced a 
local and specific deacetylation of MIF promoter-associated H3 and H4 histones. Curiously however, 
the local deacetylation of histones did not affect chromatin accessibility as revealed by chromatin 
accessibility by real-time PCR (CHART-PCR). Nonetheless, the deacetylation of the MIF promoter 
was associated with an impaired recruitment of RNA polymerase II and Sp1 and CREB, two 
transcription factors eseential to drive basal MIF gene transcription. Overal, this study describes a new 
molecular mechanism by which HDACi inhibit MIF gene expression, and suggests that inhibition of 
MIF expression by HDACi may contribute to the antitumorigenic effects of this class of drugs. 
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5 EPIGENETIC CONTROL OF MIF EXPRESSION 
 
 
 
Thierry Roger, Jérôme Lugrin, Xavier C. Ding, Thierry Calandra 
 
 
 
In MIF Handbook, Edited by Richard Bucala, World Scientific Publishing Co. Pte. Lte., New 
Jersey, 2011. Chapter II.1 
 
 
 
This commissioned manuscript summarizes our current knowledge about the epigenetic 
mechanisms involved in the control of MIF gene expression. 
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5.1 Abstract 
 Covalent modifications of DNA by methylation and of histones by acetylation are two main 
mechanisms by which epigenetics regulates gene expression under physiological and pathological 
situations. Inhibitors of DNA methyltransferases and histone deacetylases (HDACs) are potent anti-
cancer drugs, displaying anti-inflammatory and immunomodulatory activities. MIF is a 
proinflammatory cytokine involved in the pathogenesis of inflammatory, autoimmune and infectious 
diseases. Lately, MIF has been shown to promote tumorigenesis, suggesting that epigenetic 
mechanisms participate in the control of MIF expression. Of note, the MIF gene lies in a CpG island, a 
DNA context prone to regulation by methylation. Yet, the MIF promoter is hypomethylated in primary 
and tumor cells, and demethylating agents do not affect MIF expression. In contrast, HDAC inhibitors 
impair MIF mRNA and protein expression in vitro and in vivo. At the molecular level, HDAC 
inhibitors decrease the recruitment of the basal transcriptional machinery to the MIF promoter and 
thereby inhibit MIF transcription. These data indicate that HDACs are important regulators of MIF 
expression. Therefore, inhibition of MIF expression may contribute to the anticancer and anti-
inflammatory activities of HDAC inhibitors.  
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5.2 Epigenetics 
 All cells from a given organism contain essentially the same DNA information. 
Developmental specification relies on qualitative and quantitative differences in gene expression, 
which for obvious reasons of parsimony, is primarily controlled at the level of transcription. In recent 
years, epigenetics, defined as all meiotically and mitotically heritable changes in gene expression that 
are not coded in the DNA sequence (1), has profoundly transformed our vision of how gene 
expression is regulated. 
Epigenetics comprises three main and inter-related mechanisms: DNA methylation, small 
interfering RNAs and post-transcriptional modifications of histones (2). Specific panels of epigenetic 
modifications shape the transcriptional program in a cell-specific manner. As such, the epigenome 
plays a central role in conserving cell characteristics by maintaining specific patterns of gene 
expression during somatic cell division (3-6). Yet, the epigenome is dynamic and flexible and 
accommodates transcriptional changes during development. Most importantly, epigenetic 
modifications have been directly linked to the dysregulated gene expression characterizing numerous 
human diseases (7). Reflecting the great interest of biomedical research in epigenetics, ambitious 
projects and initiatives (NIH Roadmap Epigenomics Program, ENCODE project, AHEAD project and 
the Epigenomics NCBI browser) have been developed to provide highly comprehensive epigenomic 
maps in human stem cells and in healthy and diseased tissues (8, 9). In this chapter, we will focus our 
attention on DNA methylation and histone acetylation as possible mechanisms involved in the control 
of MIF gene expression, as no MIF-specific micro-RNA (miRNA) has been identified thus far. 
5.3 DNA Methylation 
 DNA methylation is probably the most studied epigenetic modification in mammals. The 
reversible covalent modification of 5’-methyl cytosine residues mainly occurs in the context of CpG 
dinucleotides. DNA methylation is catalyzed by DNA methyltransferases (DNMTs). Around 3% of 
cytosines are methylated in the human genome. Repetitive genomic DNA sequences are heavily 
methylated whereas CpG rich regions of the genome, also known as CpG islands, are commonly 
unmethylated in normal cells. The CpG islands are not randomly distributed. About half of these are 
localized in the promoter region of genes that have a widely expressed, such as MIF. 
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DNA methylation is usually associated with repressed gene expression. The methyl groups 
added by DNMTs protrude from cytosines and affect gene transcription through two main 
mechanisms. First, they inhibit the binding of transcription factors that positively regulate 
transcription. Second, they recruit methyl-CpG-binding proteins and other types of proteins that are 
involved in histone modification, chromatin compaction and gene silencing (10, 11). 
DNA hypomethylation was one of the very first epigenetic alteration reported in human cancer (12). 
Interestingly, dysregulated DNA methylation have also been reported in neurological disorders and 
autoimmune diseases (7). Yet, very little is known about the mechanisms involved in DNA 
demethylation (10,11). Although tumor cells have globally 20-60% less 5-methyl-cytosine 
methylation than normal cells, they also contain subsets of hypermethylated genes. Indeed, 
transcriptional silencing of tumor suppressor genes resulting from the hypermethylation of CpG island 
promoters is a common hallmark of tumor cells (13, 14). DNA demethylating agents have been 
developed to revert aberrant gene silencing in cancers. The nucleoside analog 5-Azacytidine (5-Aza-
CR; azacitidine, Vidaza®) and its derivative 5-Aza-2-deoxycytidine (5-Aza-CdR, decitabine, 
Dacogen®) have been approved for the treatment of all subtypes of myelodysplastic syndrome (15-
17). 
5.4 Post-transcriptional modifications by histone deacetylases 
 The nucleosome, the basic repeating unit of chromatin, is composed of a 147 bp section of 
DNA wrapped around an histone octamer composed of two copies of each of the four core histones 
H2A, H2B, H3 and H4. Histones are subjected to post-transcriptional covalent modifications at 
amino-terminal tails through acetylation, ubiquitination and sumoylation of lysine, methylation of 
arginine and lysine, and phosphorylation of serine and threonine. Histone acetylation usually 
associates with specific histone methylation marks (7). Each modification affects the structure and the 
function of the chromatin. The open structure of transcriptionaly active euchromatin is enriched in 
acetylated and trimethylated H3K4, H3K36 and H3K79 histones, whereas the transcriptionaly inactive 
heterochromatin is characterized by hypoacetylated and highly methylated H3K9, H3K27 and H4K20 
histones. 
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 Histone acetylation is controlled by the antagonistic action of two enzyme families: histone 
acetyl transferases (HATs) and histone deacetylases (HDACs). HATs catalyze the transfer of an acetyl 
group from acetyl-coenzyme A to an amino-group of lysine residues of histones. Conversely, HDACs 
catalyze the hydrolysis of acetamides resulting in histone deacetylation. The name HDAC was coined 
because histones were the first substrates identified for lysine deacetylases (18). However, HDACs 
deacetylate numerous non-histones proteins such as tubulin, heat shock proteins, steroid receptors and 
nuclear import and transcription regulators (19, 20). HDACs are classified into two main sub-families: 
HDAC1-11 and the sirtuins (21). In the following sections, we will use HDACs as a generic term 
referring to HDAC1-11. 
 Aberrant gene expression due to inactivation of HATs or overexpression of HDACs is 
common in cancer cells. Moreover, dysregulated recruitment of HDACs to promoters is associated 
with transcriptional repression, notably that of cell-cycle modifiers and tumor suppressor genes, 
thereby contributing to oncogenesis (14, 22-24). These observations strengthened the development of 
pharmacological inhibitors of HDACs as novel cancer therapeutics. Indeed, HDAC inhibitors 
counteract cancer development by blocking DNA synthesis and inducing growth arrest, differentiation 
and apoptosis of tumor cells. They also reduce tumor angiogenesis, metastasis and invasion. 
Suberoylanilide hydroxamic acid (SAHA, vorinostat, Zolinza®) and depsipeptide (romidepsin, 
Istodax®) have been approved for the treatment of cutaneous T-cell lymphoma (17) and numerous 
additional HDAC inhibitors are now being tested in clinical trials. 
Specific patterns of histone modifications by methylation and acetylation correlate with the 
expression of inflammatory and immune genes. HDAC inhibitors have been recently reported to exert 
potent anti-inflammatory and immunomodulatory activities in vitro and in vivo. HDAC inhibitors 
improved outcome in models of inflammatory and auto-immune diseases such as sepsis, rheumatoid 
arthritis, lupus, autoimmune encephalitis, multiple sclerosis, graft versus host disease, asthma and 
colitis (25-31). Therefore, HDAC inhibitors are attractive therapies not only for the treatment of 
oncologic disorders, but also possibly for immune-related diseases (32). 
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 Numerous experimental, pre-clinical and clinical observations have ascribed a central role for 
MIF in the pathogenesis of inflammatory, autoimmune and neoplastic diseases (33-35). Considering 
that these diseases are characterized by dysregulation of epigenetic marks, we hypothesized that 
epigenetic mechanisms may participate in the control of MIF expression. Since epigenetic 
modifications profoundly affect gene transcription, we will first summarize our current knowledge 
about the various DNA binding sites and trans-acting transcription factors controlling MIF gene 
expression. 
5.5 MIF gene structure, expression and transcriptional regulation 
5.5.1 MIF gene structure and expression 
The first sequence of a human MIF cDNA and of the MIF gene were reported by Weiser et al. 
in 1989 (36) and by Paralkar and Wistow in 1994 (37), respectively. A single MIF gene spans 
nucleotide positions 24236191 to 24237414 on chromosome 22 (22q11.2). This region of 
chromosome 22 is in syntenic conservation with part of mouse chromosome 10 containing the Mif 
gene (38). Also located on chromosome 22 (22q11.23), D-dopachrome tautomerase is the only 
potential human MIF paralog (39). The MIF gene is composed of three exons of 108, 173 and 67 bp 
interspaced by two introns of 189 and 95 bp (Figure 1). A single RNA initiation start site located 97 
bp upstream of the methionine codon is used to transcribed a 0.8 kb mRNA (37). The 345 bp open-
reading frame of MIF mRNA encodes for a 115 amino acid nonglycosylated protein of 12.5 kD. 
Sequence analyses of the MIF gene revealed that it does not contain a TATA box but 
numerous CpG dinucleotides forming a CpG island. A CpG island is defined as a sequence of at least 
200 bp with a G+C content of 50% or more and an observed to expected CpG dinucleotide ratio 
greater than 0.6. The MIF CpG island spans approximately 1.2 kb, starting 300 bp upstream of the 
transcriptional start site (Figure 2). In agreement with the fact that broadly expressed genes are 
typically lying in CpG islands, MIF is constitutively expressed as a single mRNA species of 0.8 kb in 
virtually all organs and cell types (summarized in (34)). 
 MIF gene expression increases through the action of cytokines (tumor necrosis factor, 
interferon-γ, interleukin(IL)-1, IL-2) (40-44), mitogens (40-44), microbial products (40, 41, 45-47)), 
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glucose (48), low-density lipoproteins (49, 50), UV-B (51), hypoxia (52, 53) and hormones 
(glucocorticoids, corticotropin-releasing factor [CRF], human chorionic gonadotropin, angiotensin) 
(54, 55). Of great interest, MIF is commonly over-expressed in prostate, breast, colon, brain, skin and 
lung cancers (56-63). Altogether, the expression patterns of MIF, its well-characterized pro-
inflammatory, pro-proliferative, pro-survival and pro-angiogenic biological activities point towards a 
crucial role of MIF in the pathogenesis of infectious, inflammatory, auto-immune neoplastic diseases 
(33-35). 
5.5.2 MIF gene transcriptional regulation 
Despite the involvement of MIF in the pathogenesis of numerous diseases, few studies have 
analyzed the molecular mechanisms underlying the transcriptional regulation of MIF. The MIF 
promoter region contains putative DNA binding sites for transcription factors such as activator 
protein-1 (AP-1), nuclear factor (NF)-κB, E-twenty six (Ets), GATA, cAMP-responsive element 
(CRE) binding protein (CREB), specificity protein 1 (Sp1), hypoxia-inducible factor (HIF) and a 
glucocorticoid receptor (GR). The first insights about MIF gene transcriptional regulation were 
obtained by the analysis of the activity of mouse Mif promoter reporter constructs in rat anterior 
pituitary cells. A CRE site in the vicinity of the transcriptional start site of the mouse Mif gene (located 
at position -48/41) was shown to mediate forskolin- and CRF-induced Mif promoter activation (64). 
Subsequently, Baugh et al. reported that hypoxia and HIF-1α activate human MIF promoter activity 
through a HIF responsive element (HRE located at position +25). Conversely, CREB over-expression 
decreased MIF promoter activity under hypoxic conditions, whereas disruption of a proximal (-20/-11) 
CRE site increased HIF-1α-mediated MIF promoter activity (52). The functional role of the HRE site 
in response to hypoxia was recently confirmed (65). We have shown that CREB and Sp1 interact with 
proximal CRE (-20/-11) and Sp1 (-42/-34) sites in the human MIF promoter to positively regulate 
constitutive promoter transcriptional activity in human monocytic (THP-1), epithelial (HeLa and 
A549) and keratinocytic (HaCat) cell lines and in peripheral blood mononuclear cells (PBMCs). The 
CRE and Sp1 sites also cooperate to mediate microbial product-induced MIF gene expression in 
monocytic cells (66). The CRE site has also been reported to relay glucocorticoid-induced MIF gene 
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expression in CEM-C7 T cells (54). Altogether, these studies indicate that DNA regulatory elements 
surrounding the transcriptional start site play a central role in controlling MIF gene transcription. Yet, 
several lines of evidence suggest that more distant regulatory elements also may have a functional role 
(Figure 5.1). For example, disruption of a distal consensus GR element (GRE at -742) completely 
abolished glucocorticoid-inducible MIF promoter activity (54). Moreover, NF-kB recruitment to 
putative kB sites at -2538 or -1389 trans-activates MIF promoter in response to IL-1b and TNF in 
endometrial cells (42, 43). 
 The MIF gene contains two major functional polymorphisms, a five to eight CATT 
tetranucleotide repeat at -794 (67) and a G/C single nucleotide polymorphism at -173 (68) (Figure 
5.1). These polymorphisms have been reported to modulate MIF promoter activity, to correlate with 
MIF expression levels, and to be associated with the susceptibility to or the outcome of infectious, 
inflammatory, autoimmune and neoplastic diseases as discussed in other chapters of this book. The 
exact mechanisms whereby these polymorphisms affect MIF gene transcriptional activity remain 
poorly understood. The -173*C SNP creates a putative AP-4 DNA binding site (68). HMG box-
containing protein 1 (HBP1), a known negative regulator of tumorigenesis, has recently been proposed 
to inhibit MIF gene transcription in prostate cancer cells by interacting with a sequence (-811/-792) 
covering five CATT repeats (69). 
 
Figure 5.1. Structure of the MIF gene and MIF mRNA. The three MIF exons are represented by black 
boxes. The κB, glucocorticoid response element (GRE), specificity protein 1 (Sp1), cAMP-responsive element 
(CRE) and hypoxia-inducible factor response element (HRE) that have been functionally characterized are 
depicted by grey boxes. Their localization is relative to the transcriptional start site set at +1. Vertical arrows 
indicate the positions of the CATT5–8 tetranucleotide microsatellite and the -173*G/C single	   nucleotide 
polymorphism (SNP). The translational start codon (ATG at +98/+100) and stop codon (TAA at 346+/+348) 
are pinpointed in the MIF mRNA. 
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5.6 Epigenetic control of MIF expression 
5.6.1 The MIF promoter is not methylated 
 The human MIF promoter contains numerous CpG sites typically found in the proximal 
promoter of housekeeping genes (Figure 5.2). Two CpG sites are part of the proximal Sp1 and CRE 
binding sequences implicated in basal MIF promoter activity (66). To test whether CpG methylation 
affects MIF gene expression in THP-1, HeLa, A549 and HaCat cell lines, we sequenced the proximal 
MIF promoter region using sodium bisulfite-treated genomic DNA, in which 5-methyl-cytosines are 
protected from bisulfite-induced conversion to uracils. These analyses focused on 34 CpG sites 
confined in a region extending from position -300 to +1. Only two methylated cytosines located at -
211 and -121 were detected in one out of five sequences in HaCat keratinocytes and THP-1 monocytic 
cells. Thus, the proximal MIF promoter is essentially not methylated in cell lines of different origins 
(70). Given that hypomethylation of the MIF promoter could account for higher MIF mRNA 
expression in tumor cells compared to normal cells, we analyzed CpG methylation in primary cells by 
bisulfite DNA sequencing. Two methylated cytosines located at -65 and -28 were detected among 12 
sequences (408 CpG sites analyzed) obtained from PBMCs isolated from three healthy subjects. 
Altogether, these data indicate that methylation of CpG sites within the proximal MIF promoter is a 
very rare event and does not account for increased MIF expression in tumor cell lines. 
 
Figure 5.2. The MIF gene is located in a cytosine guanine dinucleotide (CpG) island. In silico analysis of 
CpG sites (vertical lines) within the human MIF gene. MIF exons are depicted by grey boxes. 
 
5.6.2 Inhibition of DNA methyl transferases (DNMTs) does not affect MIF gene expression 
 CpG island shores that refer to regions of lower CpG density close to CpG islands are 
subjected to methylation (71). Moreover, methylation of CpG sites located in coding sequences or 
distant from transcriptional start sites have been reported to affect gene expression (72, 73). We thus 
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explored whether methylation of CpG sites outside the proximal MIF promoter influences MIF gene 
expression. As illustrated in Figure 5.3, treatment of epithelial (A549 and HeLa), keratinocytic 
(HaCat) and myeloid (HL-60, KG1a, U-937, THP-1) cell lines with 5-Aza-CdR does not alter MIF 
mRNA expression. Similar results were obtained with bone-marrow derived macrophages (66). This 
groundwork argues against a role for DNA methylation as an epigenetic mechanism affecting MIF 
gene expression in tumor cell lines. 
 
Figure 5.3. Inhibition of histone deacetylases (HDACs), but not of DNA methyl transferases (DNMTs), 
inhibits MIF mRNA expression. A549, HaCat, HeLa, HL60, KG1a, U937 and THP1 cells were cultured for 
18 hours with or without 5-aza-2'-deoxycytidine (5-Aza-CdR at 5 µM), an inhibitor of DNA methyl transferases 
or trichostatin A (TSA at 1 µM), an inhibitor of histone deacetylases (HDACs). MIF and p21 (CDKN1A) 
mRNA expression was analyzed by northern blotting. EtBr: ethidium bromide. 
 
5.6.3 Inhibition of histone deacetylases (HDACs) impairs MIF gene expression 
 Dysregulated HDAC activity contributes to abnormal gene expression in tumors. Considering 
that MIF is overexpressed in tumor cells and that MIF levels correlate with tumor aggressiveness and 
metastatic potential (59, 74, 75), HDACs were attractive candidate molecules regulating MIF gene 
expression. 
Trichostatin A (TSA), a natural hydroxamic acid that has inspired the design of many 
synthetic HDAC inhibitors including SAHA (76), is widely used to assess the role of HDACs in vitro 
and in vivo. Valproic acid (VPA) is a chemically unrelated HDAC inhibitor used to treat epileptic 
seizures and bipolar disorders. TSA, SAHA and VPA powerfully inhibited MIF mRNA expression in 
a time- and dose-dependent manner in a panel of tumor cell lines (A549, HeLa, HaCat, HL-60, KG1a, 
U-937 and THP-1), in B16 melanoma and in primary macrophages (Figure 5.3 and (70)). The 
inhibitory effect of TSA on MIF expression was specific as TSA reactivated the expression of the 
CDKN1A gene (encoding for the p21/WAF cell-cycle inhibitor). TSA reduced MIF protein expression 
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in cell lines, whole blood and in the circulation of mice injected with TSA (70). Altogether, these data 
suggest that HDACs are important regulators of MIF gene expression. 
Combinatorial epigenetic therapies associating DNMT inhibitors and HDAC inhibitors have 
been shown to exert additive and synergistic clinical effects in patients with hematologic malignancies 
(77-79). In HeLa, HL60 and THP-1 cells, the association of 5-Aza-CdR and TSA does not amplify 
TSA-mediated inhibition of MIF mRNA expression (Roger et al., unpublished data), in line with the 
observation that the MIF promoter is hypomethylated in tumor cells. 
MIF is overexpressed in multiple types of tumors and it promotes malignancies by increasing 
survival, proliferation and migration of tumor cells (80-82), by promoting angiogenesis (74, 83, 84) 
and by altering antitumor adaptive immune responses (75, 85-87). This led us to speculate that MIF 
might be a common target of the anticancer activity of HDAC inhibitors. Similarly, considering that 
MIF is a central mediator of the pathogenesis of sepsis (45, 47, 55, 88), arthritis (89), colitis (90) and 
lupus (91), we propose that the benefit afforded by HDAC inhibitors in inflammatory and autoimmune 
diseases may be related to the inhibition of MIF expression. 
5.6.4 Mechanisms by which HDAC inhibitors inhibit MIF gene expression 
 Studies initiated to unravel the molecular mechanisms by which HDAC inhibition affects MIF 
gene expression revealed several unique features. Nuclear run-on assays demonstrated that TSA 
inhibits MIF gene transcription. Surprisingly however, chromatin immunoprecipitation analyses 
showed that TSA deacetylates histones H3 and H4 associated with the proximal MIF promoter (70). 
This observation was unexpected given that HDAC inhibitors increased overall histone acetylation. 
Yet, genome-wide expression studies have established that HDAC inhibition impacts on a minority of 
the transcriptome (2-10%) with similar proportions of genes up-regulated and down-regulated. 
Moreover, local hypoacetylation following HDAC inhibition have been previously observed within 
the High-mobility-group A2 and BCL2 genes (92, 93). 
 Because TSA reduced the acetylation of MIF promoter-associated histones, we hypothesized 
that the MIF promoter was less accessible to the transcription machinery. Indeed, chromatin 
immunoprecipitation experiments confirmed that TSA impairs the binding of Sp1, CREB and RNA 
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polymerase II to the proximal MIF promoter. Yet, challenging the concept that hypoacetylated 
chromatin forms a compact structure less accessible to transcriptional regulators, accessibility studies 
revealed that the proximal region of the MIF promoter was accessible in cells cultured either with or 
without TSA (70). Blocking protein synthesis with cycloheximide increased early on MIF mRNA 
expression without modifying the acetylation of histones associated with the MIF promoter in cells 
treated with TSA. Therefore, we assume that TSA repressed MIF gene transcription through de novo 
protein synthesis. 
5.7 Conclusions 
 The biological activities ascribed to MIF over the last 20 years put this cytokine as a central 
mediator of cell proliferation and survival, angiogenesis and inflammatory and immune responses. In 
line with these observations, pre-clinical and clinical studies suggest that MIF represents a therapeutic 
target for the treatment of immune-related and neoplastic diseases. While our understanding of MIF 
biology has improved markedly in recent years, little is known about the mechanisms controlling MIF 
gene expression. Very few studies have characterized the DNA-binding elements and cognate 
transcription factors regulating basal and stimulus-induced MIF transcription. Much less is known 
about the role of epigenetics in regulating MIF expression. Most recent data suggest that HDAC 
activity, but not DNA methylation, strongly impacts on MIF transcription. We speculate that the 
powerful inhibition of MIF expression by HDAC inhibitors contributes, at least in part, to the 
antitumorigenic and anti-inflammatory activities of these drugs. Further work will be required to more 
deeply decipher the genetic and epigenetic mechanisms controlling MIF expression in health and 
diseases. Besides increasing our knowledge on the biology of MIF, these studies may help developing 
novel MIF-directed intervention strategies for diseases associated with dysregulated MIF expression. 
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6.1 Introduction 
6.1.1 Sirtuins, the class III HDACs   
SIR (silent information regulator, initially described as MAR1 (mating-type regulator1) (1)) 
enzymes were first discovered in the late 70s and early 80s in yeast as proteins responsible for the 
silencing of the mating type loci and telomeres. Twenty years later five human cDNAs with homology 
to yeast Sir2 gene were characterized (2). Then yeast Sir2 was shown to exhibit a deacetylase activity 
that was dependent on oxidized nicotinamide adenine dinucleotide (NAD+) (3). The substrates of the 
reaction are NAD+, H2O and an acetyl-protein that are transformed by a sirtuin into nicotinamide 
(NAM), 2’-O-acetyl-ADP-ribose and deacetylated protein (Figure 6.1A). Sirtuins also possess a 
second catalytic activity that is mono-ADP-ribosyl transferases (ART) where NAD+ and a protein are 
transformed into nicotinamide and an ADP-ribosylated protein (Figure 6.1B). Mammalian Sir2, called 
SIRT (sir two like proteins) or sirtuins, are classified as class III HDACs due to their deacetylase 
activities. SIRT1-7 are distinguished according to their sub-cellular localization as well as their 
enzymatic activities (Table 6.1) (4). SIRT1 and SIRT6 are predominantly found in the nucleus, SIRT2 
is cytosolic, SIRT3-5 are found in the mitochondria and SIRT7 is a nucleolar protein. Moreover, 
SIRT1-2 are able to shuttle between cytoplasm and nucleus and SIRT3 between mitochondria and 
nucleus (5). All sirtuins except SIRT4 and SIRT7 possess NAD+-dependent deacetylase activities, and 
all sirtuins except SIRT5 and SIRT7 have a ART activity (6). The biological role of ART activity 
remains poorly understood. Like for class I, II and IV HDACs, substrates of sirtuins comprise 
acetylated histones. However the vast majority of their targets are non-histone proteins involved in a 
variety of cell functions as explained in the following chapter. 
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Figure 6.1. Schematic representations of sirtuin enzymatic activities. (A) Deacetylase activity transforms 
NAD+ and a protein acetylated on a lysine residue into nicotinamide, which inhibits deacetylase activity, 2’-O-
acetyl-ADP-ribose as a by-product and a deacetylated protein. (B) Nicotinamide can be recycled into NAD+ by 
NAMPT enzyme. Mono-ADP-ribosyl-transferase activity engages NAD+ and a protein and releases 
nicotinamide while ADP-ribosylating the protein. NAD+, oxidized nicotinamide adenine dinucleotide; NAMPT, 
nicotinamide phosphorybosyltransferase; Nic, nicotinamide. 
 
6.1.2 Targets of sirtuins 
SIRT1 is the most documented sirtuin and the list of its targets is constantly growing. SIRT1 is 
a bona fide HDAC that possesses the capacities to deacetylate histone tails on H3K9 and H4K16, to 
promote the recruitment of histone H1 and its deacetylation on K26 and overall to favor 
heterochromatin formation and gene silencing (7). The tumor suppressor p53 has been described as a 
target of SIRT1. Deacetylation of p53 K382 by SIRT1 decreases its transcriptional activity (8). p53 
deacetylation by SIRT1 has also been shown to promote cell survival and to decrease apoptosis in 
response to DNA damage and oxidative stress (9). Premature cellular senescence induced by PML 
(promyelocytic leukemia protein)-dependent acetylation of p53 is also antagonized by SIRT1 (10). In 
addition, SIRT1-deficient mice exhibit a hyperacetylated form of p53 and severe developmental heart 
defects (11). Besides histones and p53, SIRT1 deacetylates numerous proteins involved in the 
regulation of metabolism such as PGC1α, FOXO transcription factors, the nuclear liver X receptors 
(LXRs), Acetyl-CoA synthase 1 (AceCS1) and the transcription factors NF-κB p65, STAT3, c-Jun 
and FOXP3 (12-14). 
SIRT1 and SIRT2, acting in couple with CBP/p300, regulate of the acetylation of histone H3 
on H3K56 (15,16). SIRT2 deacetylates H4K16 during the cell cycle and has been proposed to favor 
the condensation of chromatin at the G2/M transition (17,18). SIRT2 colocalizes on microtubules and 
cooperates with HDAC6 to deacetylate α-tubulin on lysine 40 (19). SIRT2 was also found to 
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deacetylate FOXO transcription factors, thereby inhibiting the differentiation of adipocytes (20).  
FOXO3α is deacetylated by SIRT2 in response to caloric restriction and oxidative stress (21). 
Mitochondrial sirtuins modulate the activitiy of metabolic enzymes via their deacetylation 
(SIRT3 and SIRT5) and ADP-ribosylation (SIRT4) activity (22). SIRT3 deacetylates acetyl-coenzyme 
A synthase 2 (AceCS2) that converts acetate to acetyl-coA. AceCS2 deacetylated by SIRT3 has an 
increased activity and thus plays a positive role on energy production by promoting acetyl-coA 
synthesis, the carbon donor used in citric cycle. SIRT3 also interacts with proteins of the complex I of 
the electron transport chain, reducing ATP production in Sirt3-/- mice. SIRT3 deacetylates H3K56 in 
vivo without affecting global acetyl-H3K56 levels. Thus, SIRT3 probably does not regulate the 
expression of large portions of the genome (16). SIRT4 ADP-ribosylates and inhibits the function of 
glutamate dehydrogenase (GDH), an enzyme responsible for the conversion of glutamate in α-
ketoglutarate and ammonia. Of note, regulation of GDH is crucial for the control of insulin secretion. 
SIRT5 deacetylates and activates carbamoyl phosphate synthase 1 (CPS1) a rate-limiting enzyme in 
the urea cycle and thus indirectly plays a positive role in the amino acid catabolism (22).  
SIRT6 was described as a histone H3K9 deacetylase responsible for telomeric chromatin 
modulation. SIRT6-depleted cells exhibit abnormal telomeric structures, leading to the proposition 
that SIRT6 participates in telomere maintenance during aging (23). By deacetylating H3K9 on κB 
promoters, SIRT6 attenuates the occupancy of p65 and transactivation by NF-κB. SIRT6-deficient 
cells have hyperacetylated H3K9 on κB promoters and enhanced expression of NF-κB-dependent 
genes (24). 
Nucleolar SIRT7 associates with actively transcribed ribosomal RNA (rRNA) genes and 
interacts with RNA polymerase I. Overexpression of SIRT7 increases RNA polymerase I transcription 
whereas knockdown of SIRT7 and inactivation of SIRT7 enzymatic activity by mutation or chemical 
inhibition with nicotinamide decrease transcription of rRNA genes (25). 
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Table 6.1. Mammalian sirtuins, their subcellular localization, enzymatic activitiy, substrate and biological 
function. Adapted from Taylor et al. 2008 (6) and Haigis & Sinclair, 2010 (4). 
Sirtuin Subcellular 
localization 
Enzymatic 
activities 
Substrates Biological Functions Phenotypes associated 
with knockout mice 
SIRT1 Nucleus Deacetylase Histones H1(K26), 
H3(K9, K14), 
H4(K16), H2A.Z, 
p53, NF-κB p65, 
FOXOs, FOXP3, c-
JUN, c-FOS, 
p300/CBP, PGC1-α, 
HIV tat… 
Glucose production, fatty-acid 
oxidation, cholesterol 
regulation, fatty-acid 
mobilization, adipokine 
regulation, fatty-acid 
oxidation, insulin secretion, 
neuroprotection, regulation of 
cellular differentiation, stress 
resistance, apoptosis control, 
mediator for caloric restriction 
Perinatal death, retinal, 
bone and cardiac defects 
SIRT2 Cytoplasm Deacetylase, mono-
ADP-ribosyl 
transferase 
α-tubulin, H3(K14), 
H4(K16), p53, 
FOXOs 
Tubulin deacetylation, cell 
cycle control 
Developmentally normal 
SIRT3 Mitochondria Deacetylase AceCS2, GDH, 
electron transport 
chain Complex I 
Mitochondrial protein 
deacetylation, acetate 
metabolism regulation, ATP 
production, regulation of 
mitochondrial fatty-acid 
oxidation 
Developmentally normal, 
change in AceCS2 activity 
and  ATP levels, elevated 
mitochondrial proteins 
acetylation 
SIRT4 Mitochondria Mono-ADP-ribosyl 
transferase 
GDH Amino acid-stimulated insulin 
secretion 
Appear healthy, increased 
mitochondrial GDH 
activity 
SIRT5 Mitochondria Deacetylase CPS1, cytochrome c Urea cycle regulation  Defect in the urea cycle 
SIRT6 Nucleus Deacetylase, mono-
ADP-ribosyl 
transferase 
H3(K9), NF-κB p65 Base excision repair, 
telomeric chromatin structure, 
NF-κB regulation 
Progeroid syndrome, 
profound hypoglycaemia, 
death at four weeks 
SIRT7 Nucleus ND RNA polymerase I Pol I transcription Reduced lifespan, 
cardiomyopathy 
 
6.1.3 Sirtuins, longevity and cancer and age related diseases 
The NAD+ requirement for the enzymatic activity of sirtuins suggested that these enzymes 
have evolved to sense energy and redox states coupled to the metabolic status of the cell. As studies 
initiated in the 30s had shown that calorie restriction extend lifespan, sirtuins gained broad interest to 
the scientific community when Kaeberlein et al. demonstrated in 1999 that an extra copy of the SIR2 
gene increased lifespan of S. cerevisiae whereas deletion of SIR2 conferred the opposite phenotype 
(26). In yeast, fly and mammals, Sir2 expression increases under caloric restriction. Remarkably, 
transgenic mice overexpressing SIRT1 developed a calorie restriction phenotype characterized by 
reduced body weight, fat mass and blood cholesterol levels (27). Altogether, these studies suggest a 
connection between SIRT1, calorie restriction, metabolism and longevity. 
These findings generated a considerable interest in the development of SIRT1 modulators, 
leading to the identification by high-throughput screening of the SIRT1 activator resveratrol, a plant 
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polyphenol (28). Resveratrol was known to exert anticancer, cardioprotective, anti-inflammatory, 
antidiabetic and neuroprotective effects (29). Yet, the connection between the pharmacological effects 
of resveratrol and SIRT1 activation is controversial. Whether resveratrol works through regulation of 
sirtuin activity remains questionable. In fact, most recent work suggests that resveratrol does not 
directly enhance the catalytic activity of SIRT1 (30). Additional screenings identified small molecules 
activator of SIRT1, which improved insulin sensitivity, lowered plasma glucose and increased 
mitochondrial biogenesis in genetically- and diet-induced obese rodents (31). Some of these activators 
are currently being evaluated in phase II clinical trials in patients with metabolic diseases. Overall, 
SIRT1 activation is viewed as an attractive therapy for treating metabolic disorders such as obesity 
and type II diabetes. Beside SIRT1, SIRT2-4 have been implicated in metabolic processes (6,32-34). 
It is commonly assumed that sirtuins have a positive impact on cardiac and neuronal functions. 
The role of sirtuins in cancer is more debatable. SIRT1 was shown to either inhibit or promote cell 
apoptosis by targeting p53, p73, E2F1, FOXOs and NF-κB p65. SIRT1 can act both as a tumor 
promoter and a tumor suppressor, depending on the model studied. Adding a level of complexity, 
SIRT2, SIRT5 and SIRT7 deacetylate p53. SIRT1-3 and SIRT7 are overexpressed in tumors whereas 
SIRT2 and SIRT4 are down-regulated in gliomas and myeloid leukemia cells (34-37). Yet, there is up 
to now no direct correlation between sirtuin activity and a particular type of cancer. Recent studies 
suggest that SIRT2 protects the integrity of the genome during mitosis and consequently prevents 
cancer development (38). SIRT2 has been shown to play a role in neurodegenerative disease and its 
inhibition to have neuroprotective effects against anoxic injury (39). Interestingly, SIRT2 deacetylates 
α-tubulin, a process that may contribute to increase the efficacy of tubulin poisoning drugs. 
6.1.4 Sirtuins and inflammatory disorders 
Little is known on the role of sirtuins in regulating inflammatory and immune responses. A 
correct balance in glucose metabolism is mandatory for adequate immune responses as both hypo- and 
hyperglycemia are detrimental to immune-cells functions (40). Nicotinamide 
phosphoribosyltransferase (NAMPT), also called pre-B cell colony enhancing factor (PBEF) or 
visfatin, functions as the rate-limiting enzyme in the synthesis of NAD. Thus, NAMPT directly 
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impacts on the activity of NAD-dependent enzymes such as sirtuins. NAMPT is secreted and found to 
be upregulated in several acute and chronic inflammatory disorders and consequently strongly links 
NAD metabolism to inflammation (41). Van Gool et al. reported that inhibition of NAMPT impairs 
TNF mRNA translation and TNF biosynthesis by macrophages and DCs in a SIRT6-dependent 
manner (42). In the same line, Bruzzone et al. showed that the NAMPT inhibitor FK866 causes NAD+ 
depletion in phytohemagglutinin (PHA)-activated T cells and drastically decreases cell proliferation 
and release of IFNγ and TNF, probably through the inactivation of SIRT6. In agreement, Sirt6-/- 
splenocytes secrete less IFNγ in response to concanavalin A (43). FK866 exhibits beneficial effects in 
experimental models of autoimmune encephalomyelitis (43), collagen-induced arthritis and 
endotoxemia (44). 
MRL/lpr mice that spontaneously develop systemic lupus displayed high levels of SIRT1 in 
CD4+ T cells. Moreover the level of anti-dsDNA antibodies and renal pathological scores are 
decreased in MRL/lpr mice treated with Sirt1 siRNA (45). These results clearly point towards a role of 
SIRT1 in the pathogenesis of lupus. Sirtinol, an inhibitor of SIRT2 and to a lesser extent SIRT1 
decreases airway inflammation and hyper responsiveness in a model of ovalbumin-induced allergic 
airway disease through an inhibition of the SIRT1/HIF1α/VEGF axis (46). In a model of rat lung 
trauma-hemorrhage, sirtinol reduces TNF and IL-6 levels and attenuates tissue damage in the lung 
(47). SIRT1 was also shown to stimulate HIF2α transactivation capacity by a direct interaction during 
hypoxia both in cultured hepatoma Hep3B cells and in living animals (48). SIRT1 downregualtion is 
involved in the acute metabolic decline observed in murine peripheral blood leukocytes (PBL) and 
liver cells of LPS-challenged mice. During the recovery phase, SIRT1 expression returns to normal 
levels and metabolism to homeostasis. In the liver of SIRT1-/- mice, metabolism also drops following 
LPS-challenge, but the return to homeostasis is drastically delayed (49). High levels of NAD+ are 
associated with the recruitment of SIRT1 and RelB at the TNF promoter during endotoxin tolerance, 
thereby favoring gene silencing (50). In addition, SIRT1 has been described as a central regulator of 
autophagy (51) that is known to play key roles in adaptive and innate immunity and to promote 
effector functions during infection (52). Finally, SIRT1 also regulates the activity of FOXO 
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transcription factors that regulates innate immune homeostasis in Drosophila (53). All these studies 
argue in favor of a pro-inflammatory role for sirtuins and that sirtuin inhibitors may have potential for 
the treatment of inflammatory and immune-related disorders. 
Unexpectedly however, several studies have reported an anti-inflammatory role for SIRT1. 
SIRT1 expression is decreased in rats exposed to cigarette smoke extracts and in smoker patients with 
chronic obstructive pulmonary diseases. SIRT1 expression decreases in monocyte/macrophages and is 
associated with an increase of both expression and acetylation of NF-κB p65 and increased production 
of pro-inflammatory mediators (54-56). The reasons why sirtuins promotes both as pro- and anti-
inflammatory recations are obscure and remain to be clarified. The discrepancies may originate from 
the different experimental settings, such as energetic status, timing or tissue and cell-type specific 
sirtuin expression (57). Of note, there is currently no information available on the role of sirtuins in 
host response to microbial infections and their possible implication in the pathophysiology of sepsis. 
6.1.5 Small molecules inhibitors of Sirtuin activities 
The structural differences of the active site of HDAC1-11 and sirtuins render sirtuins 
insensitive to the action of inhibitors of class I, II and IV HDACs. Several sirtuins inhibitors have been 
developed (Table 6.2). Sirtinol, identified by yeast cell-based phenotypic screening, is more potent 
towards SIRT2 (IC50 38µM) than SIRT1 (IC50 131µM), but its effects on the other human sirtuins are 
not known (58,59). Cambinol is a chemically stable sirtuin inhibitors related to splitomicin, a molecule 
inhibiting Sir2 and Sir2 homologues in yeast (60). Cambinol was identified as a sirtuin inhibitor that 
competes with the substrate and not with NAD+, thus cambinol does not interfere with other NAD+ 
binding enzymes. Cambinol inhibits SIRT1 (IC50 56 µM), SIRT2 (IC50 59 µM) and, less potently, 
SIRT5 (IC50>300 µM) (61). Cambinol has antitumor activity in preclinical models, which results at 
least from an increased acetylation of p53 (62). Furthermore, cambinol-induced inhibition of SIRT1 
sensitizes cells to chemotherapeutic drugs (61). 
Recently specific inhibitors of SIRT1 and SIRT2 have been developed (Table 6.2). EX-527 
was identified by high-throughput screen using bacterially expressed human SIRT1 and its activity on 
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mammalian cells has been confirmed in vitro using the Fluor-de-Lys deacetylation assay (63). EX-527 
is a selective and highly potent (IC50 98 nM) SIRT1 inhibitor which promotes p53 acetylation (63). 
AGK2 was identified by in vitro screening using a fluorometric assay on a library of structural 
analogues of known SIRT2 inhibitors. AGK2 is a strong inhibitor of SIRT2 (IC50 3.5 µM) that has a 
weak effect on SIRT1 (IC50 > 50 µM) and SIRT3 (IC50 > 50 µM) activity. In a cellular model of 
Parkinson’s disease, AGK2 reduces α-synuclein toxicity. The protective effect is associated with 
increased acetylation of tubulin (64). The development of specific inhibitors will allow fine temporal 
inhibition of sirtuins in a variety of experimental systems and a better comprehension of sirtuin 
function. Unfortunately, despite great efforts, no inhibitor targeting in vivo only one specific sirtuin 
isoform has yet been obtained (58). 
Table 6.2. Structure and IC50 of selected sirtuins inhibitors. Adapted from Cen et al., Biochimica et 
Biophysica Acta, 2009 (58). 
Compound Cambinol Sirtinol EX-527 AGK2 
 
 
 
 
 
 
 
 
IC50 SIRT1 56 µM 131 µM 98 nM >50 µM 
IC50 SIRT2 59 µM 38 µM Not determined 3.5 µM 
 
6.1.6 Rational for the use of sirtuin inhibitors as anti-inflammatory agents 
Depletion of NAD+ by FK866 has been proposed to decrease TNF and IFNγ secretion by T 
lymphocytes via an inhibition of of SIRT6 activity (43) and to reduce inflammatory parameters in 
rheumatoid arthritis (44). Morover, we reported in chapter 2 that inhibition of class I and II HDACs 
protects animal from toxic shock and severe sepsis (65). As sirtuins share many substrates with 
HDAC1-11, we hypothesized that sirtuins can play a role in the modulation of innate immune 
responses. To verify our hypothesis, we tested whether pharmacological inhibition of SIRT1 and 
SIRT2 modulate innate immune responses to microbial products and infections in vivo and in vitro. 
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6.2 Material and Methods 
6.2.1 Ethics statement 
All animal procedures were approved by the Office Vétérinaire du Canton de Vaud 
(authorizations n°876.6 and 877.6) and performed according to our institution guidelines for animal 
experiments. 
6.2.2 Mice, cells and reagents 
Eight to 12-week-old female BALB/c mice (Charles River Laboratories) were housed under 
specific pathogen-free conditions and were acclimatized for at least one week before experimentation. 
Mouse bone marrow precursors were cultured in Iscove modified Dulbecco medium (IMDM), 50 µM 
2-mercaptoethanol (βME) and 30% of filtered L929 cells supernatant to obtain bone marrow-derived 
macrophages (BMDMs). Splenocytes were cultured in RPMI medium containing 2 mM L-glutamine 
and 50 µM βME. Human whole blood assay was performed as previously described (66). Human 
PBMCs were isolated from buffy coats of healthy blood donnors using a Ficoll-Paque Plus (GE 
Healthcare) gradient centrifugation procedure. Mouse RAW 264.7 macrophages (ATCC TIB-71) were 
cultured in RPMI 1640 medium containing 2 mM L-glutamine. All media contained 10% heat-
inactivated fetal calf serum (Amimed, Bioconcept), 100 UI/ml penicillin and 100 µg/ml streptomycin. 
Trichostatin A, cambinol and DMSO were from Sigma-aldrich. Sirtinol, EX-527 and AGK2 
were from Tocris Bioscience. Microbial products were: Salmonella minnesota ultra pure LPS (List 
Biologicals Laboratories), Pam3CSK4 lipopeptide (EMC microcollections), CpG motif containing 
oligonucleotide (Invivogen) and heat-inactivated Escherichia coli (E. coli) O18, Klebsiella pneumonia  
caroli (K. pneumonia), Staphylococcus aureus (S. aureus) and Candida albicans (C. albicans). 
6.2.3 RNA analyses by real-time polymerase chain reaction (RT-PCR) 
 Total RNA was isolated from cells using the RNeasy kit (QIAGEN). Reverse transcription of 
100 ng to 1µg was performed using the QuantiTect reverse transcription kit (QIAGEN). Relative real-
time PCR was performed with a 7500 FAST Real-Time PCR System using Syber FAST mix (Applied 
Biosystems) and specific primer pairs (Table 6.3). Amplifications consisted of 40 cycles of a 
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denaturation step at 95°C for 3s and an annealing/extension step at 60°C for 30s, with the 7500 Fast 
mode. Samples were tested in duplicates. mRNA expression was expressed in arbitrary units relative 
to mRNA expression in untreated cells and normalized with an endogenous control (Hprt or Gapdh). 
Table 6.3. Primers used in RT-PCR 
Gene name Forward Reverse 
Cd40 AGGTTTAAAGTCCCGGATGC CCTTTGGTTTCTTGACCACCT 
Gapdh CTCATGACCACAGTCCATGC  CACATTGGGGGTAGGAACAC  
Hprt GTTGGATACAGGCCAGACTTTGTTG GATTCAACTTGCGCTCATCTTAGGC 
Ifng TGAGTATTGCCAAGTTTGAGGTCA CGGCAACAGCTGGTGGAC 
Il1b TGAAGTTGACGGACCCCAAA TGATGTGCTGCTGCGAGATT 
Il2 TTTGAGTGCCAATTCGATGA AGGGCTTGTTGAGATGATGC 
Il6 AGCAGTAGCAGTTCCCCTGA  AGTCCCTTTGGTCCAGTGTG  
Il12b  GGAAGCACGGCAGCAGAATA  AACTTGAGGGAGAAGTAGGAATGG  
Irf8 GGGTCCAGAGCAGCTACAAG TGTCGACCCTGTCTGTTGAG 
Klf4 CCAAAGAGGGGAAGAAGGTC CTGTGTGAGTTCGCAGGTGT 
Ly6c1 GCCAATCAGGGATCCTAACA AGCTCAGGCTGAACAGAAGC 
Maf AAGGAGGAGGTGATCCGACT TCTCCTGCTTGAGGTGGTCT 
Mafb CATCACCATCATCACCAAGC AGAAGCGGTCCTCCACACTA 
Md2 CAACTCCTCCGATGCAATTA  GGCACAGAACTTCCTTACGC  
Nlrp3 CTTCTCTGATGAGGCCCAAG GCAGCAAACTGGAAAGGAAG 
Nos2 CTCTGACAGCCCAGAGTTCC GAAAGGGAGAGAGGGGAGG 
Sfpi1 CTTCCAGTTCTCGTCCAAGC TTTCTTCACCTCGCCTGTCT 
Tlr1 CAATGTGGAAACAACGTGGA  TGTAACTTTGGGGGAAGCTG  
Tlr2 AAGAGGAAGCCCAAGAAAGC  CGATGGAATCGATGATGTTG  
Tlr4 ACCTGGCTGGTTTACACGTC  CTGCCAGAGACATTGCAGAA  
Tlr6 CAGAACTCACCAGAGGTCCAA  CGAGTATAGCGCCTCCTTTG  
Tlr9 ACTGAGCACCCCTGCTTCTA  AGATTAGTCAGCGGCAGGAA  
Tnf CCAGGCGGTGCCTATGTCT  GGCCATTTGGGAACTTCTCAT  
 
6.2.4 Cytokine measurements 
 Cell culture supernatants or plasma were collected to measure the concentration of cytokines. 
Mouse TNF, IL-6, IL-1β and IFNγ were measured using DuoSet ELISA kits (R&D Systems). For 
human whole blood and human PBMC/monocyte supernatants, TNF and IL-6 concentrations were 
measured using WEHI 164 clone 13 mouse fibrosarcoma cells (TNF) or 7TD1 mouse-mouse 
hybridoma cells (IL-6) bioassays (67). 
6.2.5 Nitric oxide assay 
Nitric oxide concentration was measured using dilutions of cell culture supernatants into 
Griess reagent (sulfanilamide 1%, ethylenediamine dihydrochloride N-(1-naphthyl) 0.1%, phosphoric 
acid (H3PO4) 2.5% in H2O) and compared to serial dilutions of NaNO2 as a standard. Dilutions of 
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samples and standard were incubated 10 min at room temperature in a microplate and absorbance was 
read at 550nm using a Versamax Microplate Reader (Molecular Devices). 
6.2.6 Flow cytometry 
 BMDMs were incubated with 2.4G2 monoclonal antibody (mAb) and CD40 monoclonal 
antibody (3/23-biotin revealed with CyChrome-conjugated streptavidin; BD Biosciences). Flow 
cytometric analyses were performed using a FACSCaliburTM flow cytometer and data analyzed using 
FlowJo 8.8.6 software (Tree Star, Inc.). 
6.2.7 Western blot analyses 
Cytoslic extracts of RAW 264.7 cells were obtained by lysis for 15 minutes on ice with Hepes 
10 mM pH 7.9, KCl 10 mM, EDTA 0.1 M, EGTA 0.1 M, DTT 1 mM, PMSF 2.5 mM, NP-40 0.6%. 
Cells were centrifugated, supernatants contained cytosolic fraction. Pellets that contained nucleus were 
further rocked at 4°C in Hepes 20 mM, NaCl 0.4 mM, EDTA 1 mM, EGTA 1 mM, glycerol 10%, 
PMSF 1 mM, DTT 0.1 mM. Nuclear fractions were centrifuged, supernatants were enriched in nuclear 
proteins. Extraction buffers were completed with cOmplete Mini protease inhibitor cocktail tablets 
(Roche) and PhosSTOP phosphatase inhibitor cocktail tablets (Roche). Proteins were quantified using 
the BCA protein assay (Pierce). Cytosolic and nuclear extracts were electrophoresed through 10-12% 
polyacrylamide gels and transferred onto nitrocellulose membranes. Membranes were incubated 
overnight at 4°C with antibodies specific for phosphorylated (phospho)-extracellular regulated kinase 
1/2 (ERK1/2), total-ERK1/2, phospho-p38, total-p38, phospho-MEK1/2, NF-κB p65, MKP-1, acetyl-
H3 (Santa Cruz Biotechnology), and α-tubulin (Sigma). After washing, membranes were incubated for 
1 h with secondary horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG. Signals were 
revealed using the ECL Western blotting analyses system (GE Healthcare). To detect histones, acid-
soluble proteins were extracted and analyzed by Western blotting as described previously (68) using 
acetylated histones H3 antibodies (06-755 Millipore). 
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6.2.8 Cell viability assay 
Cells were cultured in duplicates or triplicates in 96-well plates in the presence or absence of 
drugs and stimuli for 18 h. Cell viability was indirectly assessed using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)-fromazan assay (Merck). 
6.2.9 In vitro microbial growth 
 K. pneumoniae caroli and E. coli O18 were cultured overnight at 37°C in LB (K. pneumoniae) 
or TSB (E. coli) broth. C. albicans was cultured overnight at 30°C under agitation in YEPD broth. The 
following day, 40 µl of microbial suspension were diluted in 4 ml LB broth or YEPD containing 0, 
3.1, 12.5, 50 or 200 µM cambinol and incubated at 37°C under agitation. Optical densities (OD640) 
were read each hour during 6 h. 
6.2.10 In vivo models 
Klebsiella pneumoniae sepsis: 18-60 CFU of K. pneumoniae caroli were injected intra-nasally 
into mice treated with cambinol (10 mg/kg i.p. once per day for three consecutive days starting 24 h 
before bacterial challenge). Blood was collected 3 days after infection to quantify circulating bacteria. 
Body weight and survival of mice were followed at least once daily. 
LPS-induced shock: Mice were injected with 350 µg LPS i.p. Cambinol (10mg/kg i.p.) was 
injected 1 h and 24 h after LPS challenge. Blood was collected 1 h and 6 h after LPS challenge. Body 
weight and survival of mice were followed at least once daily. 
6.2.11   Statistical analysis 
Comparisons among treatment groups were performed using the Fisher’s exact test for 
categorical data and the Mann-Whitney tests for continuous variables. The Kaplan-Meier method was 
used for survival and differences were analyzed by the log-rank sum test. The analyses were 
performed using PRISM (GraphPad Software, La Jolla, CA). All reported P values are two-sided and 
values of less than 0.05 were considered to indicate statistical significance. 
 
119 
 
6.3 Results 
6.3.1 Cambinol inhibits cytokine secretion by BMDMs stimulated with microbial products 
To characterize the role of sirtuins in modulating innate immune responses, we first analyzed 
the ability of sirtuin inhibitors to interfere with the response of BMDMs stimulated with LPS and 
Pam3CSK4. We selected for these studies four inhibitors: cambinol that inhibits SIRT1 and SIRT2 
with a similar efficiency, sirtinol that inhibits more efficiently SIRT2 than SIRT1, EX-527 that 
inhibits SIRT1, and AGK2 that inhibits SIRT2 (Table 6.2). BMDMs were pre-incubated for 1 h with 
inhibitors used at concentrations equivalent to 0.25-, 1- and 4-fold theoretical IC50s and then exposed 
at LPS and Pam3CSK4. Cell culture supernatents were collected after 18 h to quantify TNF, IL-6 and 
IL-12p40 (Figure 6.2 and data not shown). Cambinol strongly and dose-dependently inhibited 
cytokine production by BMDMs. Sirtinol inhibited cytokine production only at the highest 
concentration (200 µM). Unexpectedly, EX-527 and AGK2 did not inhibit but rather enhanced 
cytokine production. Importantly, cambinol, EX-527 and AGK2 exhibited marginal cytotoxicity at all 
concentrations tested, whereas sirtinol at 200 µM reduced BMDM viability (measured using the MTT 
assay) around two-fold (data not shown). Overall, these results suggest that dual, but not single, 
targeting of SIRT1 and SIRT2 is required to inhibit TNF, IL-6 and IL-12p40 secretion by BMDMs. 
A B 
Figure 6.2. Effect of sirtuin inhibitors on TNF and IL-6 production by BMDMs exposed to LPS and 
Pam3CSK4. BMDMs were pre-incubated for 1 h with cambinol, sirtinol, EX-527 and AGK2 prior to 
stimulation for 18 h with LPS (10 ng/ml) (A) and Pam3CSK4 (10 ng/ml) (B). TNF and IL-6 concentrations in 
cell-culture supernatants were determined by ELISA. Results are the mean ± SD of triplicate samples from one 
experiment. 
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To further determine wether cambinol and sirtinol at non-toxic concentrations (12.5 and 50 
µM) could interfere with the response of BMDMs to bacteria and other microbial ligands recognized 
through TLRs, cells were exposed to E. coli, S. aureus and to CpG ODN, a TLR9 ligand  (Figure 6.3). 
Cambinol efficiently and dose-dependently inhibited TNF and IL-6 secretion triggered by all stimuli. 
Sirtinol inhibited TNF and IL-6 production induced by S. aureus and IL-6 production induced by E. 
coli. As cambinol was the most potent anti-inflammatory compound, we used cambinol in subsequent 
experiments analyzing the modulation of innate immune and inflammatory responses. 
 
6.3.2 Cambinol inhibits Tnf, Il6 and Il12b mRNA synthesis in BMDMs 
To define whether cambinol inhibits cytokine production by interfering with gene 
transcription, Tnf, Il6 and Il12b mRNA levels were quantified by RT-PCR in BMDMs pre-treated 
with cambinol for 1 h and stimulated with LPS or Pam3CSK4 for 1, 4 and 18 h (Figure 6.4 and data 
not shown). Tnf mRNA increased after 1 h of exposition to LPS and Pam3CSK4, whereas Il6 and Il12b 
mRNAs were detected after 4 h of stimulation. Concordant with cytokine secretion, cambinol dose-
dependently inhibited LPS- and Pam3CSK4-induced Tnf, Il6 ad Il12b mRNA up-regulation. These 
results suggest that cambinol interferes with Tnf, Il6 and Il12b transcription. 
Figure 6.3. Cambinol 
inhibits TNF and IL-6 
production by BMDMs 
stimulated with bacteria 
and CpG ODN. BMDMs 
were pre-incubated for 1 h 
with cambinol and sirtinol 
prior to stimulation for 18 h 
with E. coli  (106 CFU/ml), S. 
aureus  (5x106 CFU/ml) and 
CpG ODN (2 µg/ml). TNF 
(A) and IL-6 (B) 
concentrations in cell-culture 
supernatants were determined 
by ELISA. Results are mean 
± SD of triplicate samples 
from one experiment. 
 
A 
 
B 
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Figure 6.4. Cambinol inhibits LPS- and Pam3CSK4-induced Tnf and Il6 mRNA expression in BMDMs. 
BMDMs were pre-incubated for 1 h with cambinol prior to stimulation for 1, 4 and 18 h with LPS (10 ng/ml) 
and Pam3CSK4 (10 ng/ml). Tnf (A) and Il6 (B) were quantified by RT-PCR and results expressed as the ratio of 
cytokine to Gapdh mRNA levels. Data are mean ± SD of duplicates and are representative of three independent 
experiments. 
 
6.3.3 Cambinol inhibits IL-1β production by BMDMs 
IL-1β is produced through a multi-step process involving IL-1β mRNA induction and pro-IL-
1β synthesis following TLR stimulation, and processing of pro-IL-1β into secreted mature IL-1β 
through the action of the inflammasome (69). LPS powerfully induced Il1b mRNA in BMDMs, a 
process that was substantially inhibited upon pre-incubation with cambinol  (Figure 6.5A). To verify 
that this inhibition affected IL-1β secretion, we measured IL-1β in the cell-culture supernatants of 
BMDMs primed for 18 h with LPS (to accumulate the pro-form of IL-1β), pre-incubated with or 
without cambinol and finally exposed for 6 h to octacalcium phosphate (OCP) crystals used as 
activators of NALP3 inflammasome (70). OCP induced a significant release of IL-1β, which was 
severely reduced by cambinol (Figure 6.5B). These results confirmed the anti-inflammatory activity 
of cambinol in BMDMs. 
Figure 6.5. Cambinol inhibits IL-1β 
production by BMDMs. (A) BMDMs were pre-
incubated for 1 h with cambinol (50 µM) prior to 
stimulation with LPS (10 ng/ml). Il1b and Gapdh 
mRNA levels were quantified by RT-PCR. Data 
are mean ± SD of duplicate samples. (B) 
BMDMs were primed overnight with LPS (100 
ng/ml). Cells were washed, pre-incubated for 1 h 
with cambinol (50 µM) and stimulated for 6 h 
with octacalcium crystals (OCP, 500 µg/ml). 
Secreted IL-1β was quantified by ELISA. White 
and grey: with and without cambinol pre-
incubation, respectively. 
A B 
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6.3.4 Cambinol inhibits NO production by BMDMs 
Nitric oxide (NO) is produced during the nitrosative burst through the action of the inducible 
nitric oxide synthase (iNOS), an enzyme whose expression is induced by inflammatory stimuli. NO 
plays an important role in the clearing of phagocytosed bacteria and is involved in sustaining the 
inflammatory response (71). We assessed whether cambinol intereferes with NO production in 
BMDMs. Whereas LPS, Pam3CSK4, CpG ODN, E. coli and S. aureus promoted NO production by 
BMDMs primed with IFNγ, cambinol efficiently and dose-dependently decreased NO production 
(Figure 6.6). 
 
Figure 6.6. Cambinol dose-dependently inhibits the production of nitrites/nitrates by macrophages. 
BMDMs were primed with IFNγ (100 U/ml, 18 h). Medium was changed and cells were pre-incubated for 1 h 
with cambinol prior to stimulation for 18 h with LPS (10 ng/ml), Pam3CSK4 (10 ng/ml), CpG ODN (2 µg/ml), 
E. coli (106 CFU/ml) and S. aureus (5x106 CFU/ml). Nitrite/nitrate concentrations were determined using the 
Griess reagent. Data are mean ± SD of tripicate samples from one experiment. 
 
6.3.5 Cambinol inhibits CD40 expression by BMDMs 
CD40 is a co-stimulatory molecule expressed at the surface of antigen presenting cells 
(APCs), including macrophages, that mediates interaction with T cells. RT-PCR and flow cytometry 
analyses showed that Cd40 mRNA and CD40 membrane expression was strongly up-regulated in 
BMDMs stimulated with LPS and Pam3CSK4 (Figure 6.7). Pre-incubation with cambinol powerfully 
inhibited CD40 up-regulation, suggesting that cambinol may affect APC function of macrophages. 
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Figure 6.7. Cambinol inhibits CD40 expression in BMDMs. BMDMs were pre-incubated for 1 h with (grey 
bars) or without (black bars) cambinol prior to stimulation with LPS (10 ng/ml) or Pam3CSK4 (10 ng/ml). (A) 
Cd40 mRNA expression was quantified by RT-PCR and expressed relative to Gapdh. (B-C) After 18 h of 
stimulation, CD40 expression was analyzed by flow cytometry and expressed in mean fluorescence intensity 
(MFI). 
 
6.3.6 Cambinol does not impact on the expression of macrophage differentiation markers 
Conditional deletion of Sirt1 in the myeloid compartment generates macrophages with 
hyperacetylated NF-κB p65 and enhanced transcription of proinflammatory genes (72). Therefore, we 
analyzed whether cambinol affects monocyte/macrophage differentiation by analyzing the expression 
of relevant transcription factors and differentiation markers: Mafb and c-Maf involved in the 
regulation of macrophage differentiation and inhibition of progenitor proliferation, Klf4, Sfpi1, and 
Irf8 that coordinate the early myeloid commitment in immature progenitors and drive monocytic 
differentiation, and Ly6c1 a marker of inflammatory macrophages (73). Bone-marrow cells were 
cultured with macrophage-colony-stimulating factor (M-CSF) in the presence or the absence of 
cambinol. Gene expression was quantified by RT-PCR at days 0, 2 and 4 of differentiation (Figure 
6.8). Whereas Irf8, Klf4, Spi1 and Ly6c1 expression declined during M-CSF-induced differentiation of 
bone-marrow precursors, that of Mafb and c-Maf increased. Overall, cambinol had no effect on the 
modulation on gene expression. These preliminary results suggest that cambinol, at anti-inflammatory 
concentrations, does not affect monocyte/macrophage differentiation or tweak their differentiation 
toward a proinflammatory phenotype. 
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Figure 6.8. Cambinol does not affect the 
expression of macrophage differentiation 
markers. Bone-marrow cells were cultured in 
IMDM medium containing 10% FCS and 30% 
L929 cells supernatant as a source of M-CSF 
with (white bars) or without (grey bars) 
cambinol (25 µM). At day 0, 2 and 4 of culture, 
gene expression was quantified by RT-PCR and 
expressed relative to Hprt.  Data are mean ± SD 
of tripicate samples of one experiment. 
 
 
6.3.7 Modulation of TLR and Nalp3 expression by cambinol 
Pattern recognition molecules are essential for the sensing of microbial and danger signals. To 
start analyzing the molecular mechanisms whereby cambinol impairs the response of macrophages to 
microbial and danger products, we first quantified the expression levels of Tlr and Nalp3 mRNA in 
BMDMs pre-incubated with cambinol and stimulated for 0, 1, 4 and 18 h with LPS. RT-PCR revealed 
that Tlr1, Tlr2, Tlr6 and Nalp3 were up-regulated in LPS-stimulated BMDMs, Tlr9 almost not 
modulated and Tlr4 transiently down-regulated (Figure 6.9). Whereas cambinol did not affect mRNA 
expression of Tlr4 and Tlr6, it inhibited that of Nalp3 early on (4 h) and that of Tlr1 and Tlr2 later on 
(18 h). Surprisingly, cambinol up-regulated Tlr9 expression after 18 h. Therefore, the inhibition of 
LPS- and CpG-induced cytokine expression by cambinol (Figure 6.2-4) probably does not rely on a 
decreased TLR4 and TLR9 expression. Similarly, it is unlikely that late inhibition of Tlr1 and Tlr6 
contributes to decrease cytokine response to Pam3CSK4 and S. aureus. Yet, we should validate these 
hypotheses at the protein level. 
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Figure 6.9. Modulation of Tlr and Nalp3 expression by cambinol. BMDMs were pre-incubated for 1 h with 
cambinol (50 µM) prior to stimulation with LPS (10 ng/ml) for 1, 4 and 18 h. Tlr1, Tlr2, Tlr4, Tlr6, Tlr9 (A) and 
Nalp3 (B) expression was quantified by RT-PCR and results expressed relative to Hprt expression. Data are 
mean ± SD of duplicates determinations. 
 
Considering the above results, we decided to study the effects of cambinol on histone 
acetylation and signal transduction pathways elicited by microbial products in macrophages. Since 
these techniques require large amounts of material, we selected the mouse RAW 264.7 macrophage 
cell line as a model. Indeed, similar to what we observed in BMDMs, cambinol powerfully inhibited 
cytokine mRNA and protein expression in LPS- and Pam3CSK4-stimulated RAW 264.7 macrophages 
(data not shown). 
6.3.8 Cambinol does not increase overall histone H3 acetylation 
Inhibitors of class I and II HDACs promote global changes of histone acetylation and balance 
toward a net hyperacetylation of histones. To check wether global acetylation of histone H3 (acH3), a 
common target of class I, II and III HDACs, is modified upon cambinol treatment, we analyzed acH3 
levels in RAW 264.7 macrophages pre-incubated for 1 h with cambinol and stimulated for 4 and 12 h 
with LPS (Figure 6.10). Neither cambinol nor LPS modified global histone H3 acetylation, suggesting 
that cambinol does not act through global reprogramming of histone acetylation. As a positive control, 
trichostatin A (a pan HDAC1-11 inhibitor) strongly increased acH3 levels in LPS-stimulated cells. 
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Figure 6.10. Cambinol does not 
increase global acetylation of histone 
H3. RAW 264.7 macrophages were 
pre-incubated for 1 h with (+) or 
without (-) cambinol or TSA and 
exposed to LPS for 0, 4 and 12 h. 
Acetylated-(ac) H3 proteins were 
analyzed by Western blotting of acid-
extracted proteins. Ponceau S staining 
was used to control for equal loading.  
 
6.3.9 Cambinol does not impair NF-κB p65 translocation, but inhibits MAPK phosphorylation 
SIRT1- and SIRT2-dependent deacetylation of NF-κB p65 on Lys310 has been shown to 
modulate the expression of NF-κB-dependent genes (50,74,75). Since cambinol inhibits SIRT1 and 
SIRT2 activity, we questioned whether cambinol interferes with NF-κB p65 nuclear translocation. 
RAW 264.7 macrophages were exposed to LPS for 15-240 minutes, and we analyzed cytosolic and 
nuclear NF-κB p65 content by Western blotting (Figure 6.11). LPS promptly stimulated NF-κB p65 
nuclear translocation, a process that was not affected by cambinol pre-treatment. We will test the 
possibility that cambinol affects NF-κB signaling at the DNA level (i.e. docking of NF-κB to DNA 
and NF-κB-mediated transcriptional activity). 
Figure 6.11. Cambinol does not 
interfere with NF-κB nuclear 
translocation. RAW 264.7 macrophages 
were pre-incubated for 1 h with (+) or 
without (-) cambinol (50 µM) prior to 
stimulation with LPS (10 ng/ml). 
Cytosolic and nuclear NF-κB p65 was 
analysed by Western blotting. Results 
are representative of two independent 
experiments. 
 
 
Activation of MAPKs triggered by TLR stimulation is required for active transcription of pro-
inflammatory genes. To test whether MAPKs were targetted by cambinol, we assessed the 
phosphorylation of p38, ERK1/2 and JNK in RAW 264.7 macrophages (Figure 6.12). 
Phosphorylation of p38, ERK1/2 and JNK was detected 30 minutes upon LPS stimulation and 
elevated up to 240 minutes. Strikingly, cambinol almost fully abrogated LPS-induced p38, ERK1/2 
and JNK phosphorylation.  
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Figure 6.12. Cambinol inhibits 
MAPK phosphorylation. RAW 264.7 
macrophages were pre-incubated for 1 h 
with (+) or without (-) cambinol (50 
µM) prior to stimulation with LPS (10 
ng/ml). Expression levels of phospho 
(P-) and total p38, ERK1/2 and JNK 
were analysed by Western blotting. 
Results are representative of two 
independant experiments. 
 
Impaired phosphorylation of MAPKs mediated by cambinol may rely on the inhibition of the 
upstream MAPK kinase (MAPKK) MEK1/2, or the induction/activation of MAPK phosophatases 
(MKPs, also known as dual-specific phosphatase or DUSP). In preliminary experiments, we focused 
on MKP-1 (DUSP1), which plays a key role in the feedback negative control of MAPK activation 
upon microbial challenge (76,77). To our surprise, cambinol neither inhibited MEK1/2 
phosphorylation nor induced MKP-1 expression in RAW 264.7 macrophages (Figure 6.13). Thus, the 
mechanism by which cambinol interferes with MAPK phosphorylation remains to be identified. In 
preliminary experiments, we observed that cambinol potentiates the expression of several LPS-
inducible DUSPs. Additional work will be required to confirm the relevance of these observations at 
the protein level in relation to host response to microbial stimulation. 
Figure 6.13. Cambinol does not interfere 
with MEK1/2 activation and MKP-1 
expression. RAW 264.7 macrophages were 
pre-incubated for 1 h with (+) or without 
cambinol (50 µM) prior to stimulation with LPS 
(10 ng/ml). Phospho (P-) MEK1/2 and MKP-1 
were analysed by Western blotting. Results are 
representative of two independent experiments. 
 
 
6.3.10 Cambinol impairs cytokine production by splenocytes, whole blood and PBMCs 
The experiments described above were performed using BMDMs and RAW 264.7 mouse 
macrophages. To verify that cambinol affects the response of immune cells other than macrophages, 
we measured the cytokine response of mouse splenocytes following polyclonal stimulation with the 
superantigen toxic shock syndrome toxin 1 (TSST-1) and concanavallin A (Figure 6.14). TSST-1 
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strongly induced Il2 and Ifng mRNA levels in splenocytes. Pre-incubation for 1 h with cambinol at 25 
µM or above decreased Il2 and Ifng mRNA expression. Moreover cambinol dose-dependently 
inhibited the secretion of IFNγ by splenocytes stimulated with concanavalin A. These results indicate 
that the anti-inflammatory effect of cambinol is not restricted to monocytes/macrophages, but is also 
efficient on splenocytes. 
B 
 
A 
 
Figure 6.14. Cambinol inhibits cytokine prduction by 
splenocytes. Splenocytes were pre-incubated 1 h with 
cambinol and stimulated for 20 h with TSST-1 (2 µg/ml) 
or concanavallin A (5 µg/ml). (A) Il2 and Ifng mRNA 
levels were quantified by RT-PCR. White, unstimulated; 
grey, stimulated. (B) IFNγ was quantified by ELISA. 
 
To test the effect of cambinol on cytokine production by human primary immune cells, we 
developed a human whole blood assay and analyzed the response of peripheral blood mononuclear 
cells (PBMCs) obtained from healthy blood donors (Figure 6.15). As anticipated, stimulation of 
whole blood and PBMCs with LPS promoted the production of great quantities of TNF and IL-6 that 
were dose-dependently inhibited by cambinol. Thus, cambinol reduces cytokine production induced 
by microbial products in both murine and human primary innate immune cells. 
B 
 
A 
Figure 6.15. Cambinol inhibits LPS-induced TNF 
and IL-6 release in human whole blood and 
PBMCs.  Whole blood (A) and PBMCs (B) were pre-
incubated for 1 h with cambinol before stimulation 
for 18 h with LPS (10 ng/ml). TNF and IL-6 
concentrations were measured by bioassay. 
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6.3.11 Cambinol protects mice from lethal endotoxemia 
 We developped a model of endotoxic shock to establish whether cambinol has anti-
inflammatory properties in vivo. Mice were injected intra-peritoneally (i.p.) with LPS (17.5 mg/kg). In 
a first series of experiments, animals were sacrified 0, 1, 4, 8 and 24 h post-innoculation to quantify 
Sirt1 and Sirt2 mRNA expression in the spleen, liver and kidney (Figure 6.16). In both spleen and 
kidney, Sirt1 and Sirt2 gradually decreased during the course of the analysis. On the contrary, Sirt1 
and Sirt2 mRNA slightly increased early on in the liver (t=1-4 h for Sirt1 and t=1 h for Sirt2) and then 
returned to basal levels after 24 h. Thus, Sirt1 and Sirt2 expression is modulated in a time- and tissue-
dependent fashion during endotoxic shock. The results argue for a possible regulatory role of situins 
during endotoxemia. 
 
Figure 6.16. Expression levels of Sirt1 and Sirt2 mRNA in spleen, liver and kidney of endotoxic mice. 
BALB/c mice were injected i.p. with LPS (17.5 mg/kg). Spleen, liver and kidney were collected after 0, 1, 4, 8 
and 24 h. Sirt1 and Sirt2 mRNA levels were quantified by RT-PCR and expressed relative to Hprt mRNA 
levels. *, 0.05 > P > 0.005, ** P < 0.005 by one-way ANOVA and Dunnett's multiple comparison test for group 
comparisons, 
 
To establish whether cambinol has anti-inflammatory properties in vivo, cambinol (10 mg/kg) 
was administrated i.p. 1 h before and 24 h after LPS injection. Blood was collected 1 h after LPS 
administration to quantify TNF levels. Remarkably, administration of cambinol significantly 
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decreased TNF blood levels (P = 0.049) and increased survival from 8.3% to 46.1% (P = 0.035) 
(Figure 6.17). 
A 
 
B 
 
Figure 6.17. Cambinol protects from endotoxemia. BALB/c mice were injected i.p. with LPS (17.5 mg/kg). 
Cambinol (10 mg/kg) or diluent (DMSO) was administrated i.p. 1 h before and 24 h after LPS challenge. (A) 
TNF concentrations in blood collected 1 h after LPS challenge were measured by ELISA (n=7-8 per group). (B) 
Survival of mice (n=12-13 per group). 
 
6.3.12 Cambinol confers protection to severe sepsis 
Next, we developped a model of Klebsiella pneumoniae  (K. pneumoniae) pneumonia to 
analyze the impact of cambinol in a model of bacterial infection. Prior performing in vivo experiments, 
we tested wether cambinol possesses any intrinsic microbicidal or microbiostatic activity. Growth 
curve of K. pneumoniae cultured with increasing concentrations of cambinol ranging from 0 to 200 
µM demonstrated that cambinol had no impact on bacterial growth in vitro  (Figure 6.18). Similar 
results were obtained when analyzing E. coli and C. albicans (data not shown). 
Figure 6.18. Cambinol does not impair the growth 
of Klebsiella pneumoniae. K. pneumoniae were 
seeded in Luria-Bertani (LB) broth containing 0 
(black), 3.1 (green), 12.5 (blue), 50 (orange) or 200 
µM (red) cambinol and grown at 37°C under agitation. 
Bacterial growth was measured as the optical density 
read at 640 nm. 
 
 
Mice were infected intranasally with 18-63 CFU K. pneumonia and treated with cambinol (10 
mg/kg) or DMSO 24 h before, at the onset and 24 h and 48 h after infection. Blood was sampled 3 
days after bacterial innoculation. Bacterial loads did not significantly differ between control and 
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cambinol-treated mice, albeit being 2-fold lower in cambinol treated animals (Figure 19A). Mice 
started to die 3 days post-infection in the control group. Whereas only 13.3% of mice survived 
infection in the control group, 60% of mice survived in the cambinol group (P = 0.015; Figure 19B). 
Thus, cambinol protects mice from lethal K. pneumoniae infection. 
 
 
A 
 
B 
 
Figure 6.19. Cambinol confers protection against Klebsiella pneumoniae pneumonia. BALB/c mice (n=15 
per group) were challenged intranasally with 18-63 CFU K. pneumonia. Cambinol (10 mg/kg) or diluent 
(DMSO) was administrated i.p. 24 h before, at time of challenge, 24 h and 48 h after K. pneumonia challenge. 
(A) Blood was sampled 3 days after infection to enumerate circulating bacteria. (B) Survival of mice. 
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6.4 Discussion 
The inflammatory response can be regulated by different mechanisms that can be divided into 
gene-specific, signal-specific and cell-specific (78). Acetylation and deacetylation can influence the 
inflammatory response at these three levels. Histone modifying enzymes including HATs and HDACs 
have been shown to be important regulators of pro-inflammatory gene transcription in a gene-specific 
manner by modifying chromatin structure (79). 
In the present study, we report that cambinol, an inhibitor of SIRT1 and SIRT2, inhibits the 
expression of cytokines, nitric oxide and CD40 induced by different microbial products in 
macrophages, splenocytes, whole blood and PBMCs. Moreover, cambinol reduces the expression 
levels of TNF and protects animals from endotoxic shock. Cambinol also increases survival rate of 
mice in a model of severe K. pneumoniae pneumonia. In line with our results, reduction of NAD 
bioavailability decreased TNF production in mice challenged with LPS (44). 
Numerous studies have shown that acetylation modifies the structure or the activity of signal 
transducers and chromatin (80-83). Cambinol inhibits Tnf, Il1b, Il6, Il12b and Cd40 mRNA expression 
in LPS- and/or Pam3CSK4-stimulated macrophages, suggesting that cambinol interferes with the 
transcription of immune related genes. Surprisingly however, cambinol does not modify the nuclear 
translocation of NF-κB, a well-known target of acetylation-dependent regulation (84,85). Yet, 
cambinol drastically inhibits the phosphorylation of p38, ERK1/2 and JNK without affecting the 
activation of the upstream MAPKK MEK1/2. At first glance, these results are surprising because NF-
κB and MAPKs pathways are usually activated concomitantly by microbial products in innate immune 
cells (86). Our result could be explained by a specific action of cambinol on the MAPK pathway. 
Supporting this assumption, SIRT1 interacts with c-Jun and reduces AP-1 transcriptional activity (80). 
Moreover, sirtinol induces senescence-like growth arrest and disrupts the Ras-MAPK pathway in 
human cancer cell lines stimulated with epidermal growth factor (87). Finally, nicotinamide inhibits 
the accumulation of phosphorylated ERK1/2 during the activation of primary murine B lymphocytes 
with LPS, anti-IgM, anti-CD40 or anti-CD38 (88). Further studies will be devoted to clarify the role of 
sirtuins and sirtuin inhibitors in the regulation of MAPK activity. 
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Although there is growing evidences that sirtuins modulate immune responses, their influence 
on inflammation remains poorly understood and controversial (57). Sirtuins, and primarily SIRT1, are 
involved in the pathogenesis of lupus, experimental autoimmune encephalomyelitis, collagen-induced 
arthritis, allergic airway disease and trauma-hemorrhage (43-47). Moreover, SIRT6 is required for 
optimal TNF synthesis by macrophages and DCs (42) and TNF and IFNγ production by PHA-
stimulated peripheral blood lymphocytes (43). In line with these studies, cambinol powerfully inhibits 
the production of pro-inflammatory cytokines induced by microbial products and heat-killed bacteria 
in macrophages and splenocytes.   
We observed that cambinol inhibits IL-1β production by macrophages at least in part by 
decreasing Il1b gene expression. The NALP3 inflammasome plays a key role in controlling IL-1β 
secretion (69). SIRT1 has been reported to deacetylate and activate PGC-1α, a process that in turn 
promotes mitochondrial activity and biogenesis (89). Interestingly, activated NALP3 inflammasome 
relocalizes from the endoplasmic reticulum (ER) to perinuclear environment and co-localize with ER 
and mitochondria (90). NALP3 activation is regulated by reactive oxygen species (ROS) (91) and 
SIRT1 promotes mitochondrial biogenesis. Thus, it would be important to analyze the effects of 
cambinol and SIRT1 inhibition on ROS production by mitochondria as well as NALP3 mitochondrial 
relocalization, as it may participate to impede IL-1β production. 
Together with ROS, reactive nitrogen species (RNS) produced by phagocytes create a hostile 
milieu for pathogens (71). Deficiency in inducible nitric oxide synthase (iNOS) impairs anti-microbial 
host defenses (92,93). Our observation that cambinol inhibits the generation of RNS in response to 
LPS suggests that inhibition of sirtuins may affect bactericidal activity of phagocytes as recently 
shown for inhibition of class I and II HDACs (65,94). 
The role of sirtuins in the differentiation of immune cells is yet obscure. One study reported 
that conditional deletion of SIRT1 in myeloid cells in mice favors the development of pro-
inflammatory macrophages (72). In a model of monocyte/macrophage differentiation from bone 
marrow precursors, we could not detect any effect of cambinol in shaping the expression of key 
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transcription factors or differentiation markers specific of the monocyte/macrophages lineage. The 
relevance of these observations will be assessed by analyzing the proportions and the phenotypes of 
monocytes/macrophages in mice treated with cambinol. 
Several studies described anti-inflammatory properties of SIRT1, which have been associated 
with acetylation-dependent modulation of the activity of NF-κB and AP-1 (80,84,85). Going well 
along with these observations, we observed that the SIRT1 and SIRT2 specific inhibitors EX-527 and 
AGK2, contrary to cambinol, increase cytokine production induced by LPS and Pam3CSK4 in 
macrophages. Moreover, sirtinol, which inhibits SIRT2 more efficiently than SIRT1, has not the same 
ability as cambinol to reduce cytokine secretion. Several explanations may reconcile these 
contradictory results. 
First, sirtuins probably act in concert to control the expression of cytokine genes. The net 
effect on gene expression may result from a delicate balance between the opposing action of pro- and 
anti-inflammatory sirtuins or sirtuin-associated molecules, depending on the chromatin context. Thus 
highly specific sirtuin inhibitors like AGK2 and EX-527 may not act similar to more broad-spectrum 
inhibitors such as cambinol. Up to now, SIRT2 has not been implicated in the regulation of immune or 
inflammatory responses. Although catalytic inhibition of SIRT2 with AGK2 does not reduce LPS-
induced TNF and IL-6 release by macrophages, targeting SIRT1 and SIRT2 using cambinol impairs 
Tnf and Il6 gene expression. Moreover, depleting SIRT2 expression with shRNA in RAW 264.7 
macrophages inhibits LPS-, Pam3CSK4- and CpG ODN-induced TNF release (data not shown). It is 
possible that SIRT2 develops anti-inflammatory in conjunction with SIRT1. In the same line, Peck et 
al. have reported that inhibition of both SIRT1 and SIRT2, and not of SIRT1 alone, induces p53 
acetylation in vivo (95). We are currently developing a colony of Sirt2 knockout mice to be able to 
definitively address the role of SIRT2 in the regulation of the inflammatory and innate immune 
responses. 
A second explanation that could account for the contradictory results reported in this study 
relies on the specificity of the sirtuin inhibitors, which might be broader than claimed. Although 
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cambinol had no activity against SIRT3 and SIRT5 (61), it was not tested against other sirtuins, 
notably SIRT6 that was recently shown to participate to the post-transcriptional control of TNF 
production by dendritic cells (42). We cannot exclude a role of cambinol in inhibiting SIRT4 and 
SIRT7. In fact, combined treatment with of EX527 and AGK2 did not reproduce the effect of 
cambinol with the same efficiency (data not shown). Interestingly, cambinol showed activity when 
used at concentrations lower than its theoretical IC50. Yet, one should also recall that the IC50s of 
sirtuin inhibitors have been defined in vitro in experimental systems comprising solely sirtuins, sirtuin 
substrates and sirtuin inhibitors, which do not reflect the complexity of the environment of the 
chromatin to which sirtuins are recruited in vivo. Moreover, there is up to now no data on the stability, 
metabolism and bioavailability of sirtuin inhibitors in vivo. 
Overall, we have demonstrated that cambinol inhibits pro-inflammatory cytokine production 
by innate immune cells through a mechanisms affecting gene transcription. The precise upstream 
mechanisms used cambinol remains to be defined. Most importantly, cambinol inhibits TNF synthesis 
and increases survival during endotoxic shock and augments survival to lethal K. pneumoniae 
infection, suggesting that cambinol or other drugs of this class could be used as adjunctive therapy in 
pathologies characterized by acute or chronic inflammatory responses and in sepsis. 
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7 CONCLUDING REMARKS & PERSPECTIVES 
In contrast to our extensive knowledge of the effects of HDAC inhibitors (HDACi) in the field 
of cancer, much less is known about the influence of these drugs on the innate immune system. In this 
work, we report compelling evidences indicating that HDACi have powerful anti-inflammatory and 
immunomodulatory activities in vitro and in vivo. 
In chapter 1 and 2, we present a first comprehensive study of the effects of HDAC1-11 
inhibitors (therefater called HDACi) on innate immune responses. As summarized in the illustration 
below, we have seen that HDACi affect numerous facets of the innate immune response. Strikingly, 
expression studies revealed that HDACi act essentially as negative regulators of basal and microbial 
product-induced expression of critical immune receptors and antimicrobial products by innate immune 
cells. These results strengthen the notion of a certain specificity of HDAC inhibition in altering gene 
expression. Indeed, a global analysis of the effects of HDACi showed that they affected the expression 
of only a small proportion (less than 10%) of all cellular genes in macrophages with similar 
proportions of genes up-regulated and down-regulated. 
 
 
Figure 7.1 HDAC inhibitors block innate 
immunity. Addition of broad-spectrum 
HDAC inhibitors to macrophages stimulated 
through TLRs results in a dominant 
inhibition of gene expression (up to 60% of 
TLR-induced genes) encompassing 
suppression of all major functions of 
macrophages. Consequently, in vivo 
susceptibility to infections is increased when 
the HDAC inhibitor valproate is 
administered to mice, whereas overreactivity 
of innate immunity as observed in septic 
shock is decreased. (Professional illustration 
by Kenneth X. Probst) 
From Bode KA & Dalpke AH. Blood 
2011;117(4):1102-3.  
Comment on Roger T. et al. Blood 
2011;117(4):1205-17. 
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The molecular mechanisms by which HDACi interfere with gene expression are not fully 
understood, but are likely multiple depending on the cell type, the drug and the stimulus analyzed. In 
line with previous studies, HDACi did not reduce histone H4 acetylation and phosphorylation or 
activation of signal transduction pathways (NF-κB, MAPKs, IRFs, STAT1, AP-1) playing a crucial 
role in the initiation of inflammatory and innate immune responses. We identified a new molecular 
mechanism by which HDACi mediate their effects through the induction of the trancriptional 
repressor Mi-2β and its recruitment to the promoter region of the Il6 gene analyzed as prototypical 
HDACi-targetted cytokine. Whether HDACi act preferentially or not through Mi-2β to inhibit immune 
gene expression is presently unknown and will require broad scanning technology such as ChiP on 
chip analyses. 
Treatment with VPA remarkably reduced cytokine levels and protected mice from Pam3CSK4-
induced fulminant toxic-shock. Furthermore, VPA protected animals from cecal ligation and puncture, 
one of the most stringent models of bacterial sepsis. Whereas major advances in antimicrobial therapy 
and supportive care have reduced short-term mortality from sepsis in the last twenty years, the 
prognosis of patients with severe infections continues to be grim. Therefore, the identification of new 
treatment options for septic patients remains imperative. In light of the results reported here, we 
propose that HDACi could represent an efficacious adjunctive therapy of severe sepsis. These drugs 
may have the advantage over therapies targeting a single molecule (i.e. antibodies) to broadly dampen 
pro- and anti-inflammatory reactions by reshuffling gene expression. 
Histones themselves possess intrinsic pro-inflammatory properties. Histones H3 and H4 
released by necrotic cells during endotoxic shock are highly toxic and promote the death of endothelial 
cells. It will be of interest to study the post-translational modifications of histones circulating in septic 
animals and to analyze whether HDACi treatment modifies the acetylation status of blood histones. 
Indeed, it may represent an additional mechanism by which HDACi could be beneficial by promoting 
detoxifying and cytoprotective effects. Furthermore, it will be of primary interest to identify the exact 
DAMP(s) related to circulating histones (for example histones alone or histones complexed with 
DNA) and the molecules or PRR(s) involved in their recognition by endothelial and immune cells. 
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Considering that pro-inflammatory mediators released during the course of an infection 
coordinate the development of innate and adaptive immunity, one may anticipate that HDACi may 
interfere with the generation of pathogen-specific adaptive immune responses (i.e. the generation of 
pathogen-specific T and B cells). Several studies have shown that HDACi diminish the APC function 
of macrophages and dendritic cells, notably through down-regulating the expression of costimulatory, 
adhesion and antigen presentation molecules. We have shown that microbial uptake by phagocytes is 
impaired by HDACi. Altogether these data suggest possible adverse effects of HDACi on the 
generation of adaptive response to microbes and vaccines. 
VPA increased bacterial burden and mortality of mice infected with a sub-lethal inoculum of K. 
pneumoniae, and accelerated death rate and increased overall mortality in a model of disseminated 
candidiasis. These experiments definitely prove that HDACi hamper innate immune responses under 
pathophysiological situations, as can be expected from any treatment blocking or inhibiting the 
activity of innate receptors and cytokines. Although we used VPA as a model HDACi because of its 
low toxicity, it can be argued that VPA is employed since decades to treat epileptic patients with no 
major side effect. Yet, higher concentrations of VPA have been tested for cancer chemotherapy, 
moreover in combination with immunosuppressive therapies. 
Thus, one obvious matter is to define whether HDACi affect natural host defenses in patients. 
Although numerous phase I and II clinical trials have been performed, no definitive answer can be 
given to this crucial question for several reasons. First, clinical trials testing HDACi are typically 
performed in patients with advanced cancer who usually have confounding underlying components 
and reduced life expectancy. Second, few patients have been treated for long time periods with 
HDACi (except VPA), so that long-term toxicity is not known. Third, whether patients were treated 
prophylactically with antimicrobial agents and whether episodes of infection occurred may not have 
been always accurately reported, as the objectives of clinical trials were to assess the bioavailability, 
toxicity and response of cancer to the drugs. Nonetheless, it is worthwhile to mention that patients 
treated with HDACi such as MS-275, VPA, SAHA and ITF2357 commonly experienced hematologic 
toxicity characterized by thrombocytopenia, leucopenia and neutropenia which are major risk factors 
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for developing severe infection. In fact, episodes of severe infection have been reported in patients 
treated with HDACi with or without neutropenia. Large prospective studies will be required to settle 
the impact of HDACi on host immune status and susceptibility to infection, especially in 
immunosuppressed cancer patients. 
 
MIF is an important mediator of the inflammatory and innate immune responses, playing also a 
role in promoting cell proliferation and tumorigenesis. In chapter 4 and 5, we report that HDACi 
decrease MIF gene transcription through a local deacetylation of MIF promoter-associated histones 
that affects the recruitment of basal transcriptional machinery. This deacetylation is intriguing since 
HDACi are supposed to inhibit class I, II and IV HDACs and that these enzymes are responsible for 
deacetylation of histone tails. We speculate that this effect could be ascribed to the recruitment of 
sirtuins to the MIF promoter following treatment with HDACi. This hypothesis is relevant for two 
reasons. First, sirtuins are not sensitive to classical HDACi. Second, sirtuins expression is dose-
dependently increased by TSA in HeLa cells (results from exploratory RT-PCR analyses not shown in 
this manuscript) and down-regulation of MIF expression by TSA was dependent on de novo protein 
synthesis. To test our hypothesis, we will investigate the recruitment of sirtuins to the MIF proximal 
promoter in cells treated with HDACi. Another unexplored feature is that TSA did not impact on the 
expression levels of Sp1 and CREB, which control MIF gene basal transcription. Further work will be 
required to test whether TSA displaces the binding of Sp1 and CREB from the MIF promoter through 
a direct modification of these proteins affecting their DNA binding capacity, or through the 
recruitment of a transcriptional repressor competing with, or disrupting, Sp1 and CREB DNA binding.  
Most interestingly, infusion of TSA reduced MIF blood levels in mice, leaving open the 
possibility that HDACi impair tumorigenesis by reducing MIF bioavailability. This assumption could 
be verfied by analyzing tumor development and MIF content in a murine model of carcinogenesis in 
which animals would be treated with HDACi with or without concomitent supplementation with 
recombinant MIF. Moreover, it would be interesting to analyze MIF production by macrophages of 
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the tumor microenvironment since it is well established that the proinflammatory milieu generated by 
macrophages sustains tumorigenesis. 
 
Sirtuins are histone deacetylases whose role in immunity just begins to be explored. In 
chapter 6, we provide the results of experiments suggesting that inhibition of SIRT1 and SIRT2 using 
cambinol have strong anti-inflammatory repercussions as illustrated by reduced cytokine production. 
In line with these results, RAW 264.7 macrophages, in which Sirt1 or Sirt2 was silenced, produced 
lower levels of TNF and IL-6 in response to microbial products (data not shown). Having established a 
colony of SIRT2 knockout mice, we will be able to verify the relevance of these observations by using 
SIRT2 knockout cells. We will also use SIRT2 knockout animals to establish whether SIRT2 
deficiency influences the differentiation of monocyte/macrophages and other immune cell types in 
vivo. 
If the net anti-inflammatory effect of cambinol seems similar to the one obtained with HDACi, 
the mechanism underlying the action of the different drugs is probably different. Indeed, cambinol 
profoundly interfered with MAPK activation in macrophages stimulated with LPS, which was not the 
case for HDACi. As cambinol did not affect LPS-induced phosphorylation of the upstream MAPKK 
MEK1/2, we favor the possibility that cambinol acts through the induction of a dual-specific 
phosphatase (DUSP). MKP1 being excluded from a preliminary screen, we will persue by analyzing 
the expression of DUSPs in macrophages treated with cambinol and the effect of cambinol in 
macrophages in which DUSP expression will be silenced using siRNA. The binding partners of SIRT1 
and/or SIRT2 in the MAPK pathway will also be explored in co-immunoprecipitation studies.  
NF-κB p65 is a well-known target of SIRT1 and SIRT2. Even though we could not observe 
any effect of cambinol on LPS-induced NF-κB p65 nuclear translocation, it does not exclude an effect 
of cambinol on NF-κB p65 DNA binding or transactivating activity. These particular points will be 
verified in electrophoretic mobility shift assays, transfection studies using a NF-κB luciferase reporter 
system and chromatin immunoprecipitation of cytokine promoters. 
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Up to now, we have analyzed the effects of cambinol on only a few aspects of innate immune 
responses in vitro. Obviously, we will have to extend our analyses on dendritic cells, and to assess the 
impact of sirtuin inhibition on the expression of PRRs, the production of reactive oxygen and nitrogen 
species (ROS and RNS), and the phagocytosis and the killing of pathogens by phagocytes. The effect 
of cambinol and SIRT1 inhibition on the production of ROS by mitochondria will be particularly 
scrutinized as it has recently been reported that ROS are important for NALP3 inflammasome 
activation and thus for the secretion of IL-1β. Moreover, we have shown that inducible Il1b gene 
expression is reduced by cambinol. 
Unfortunately, almost nothing is known on the stability, metabolism and bioavailability of 
sirtuin inhibitors in vivo. Pharmacokinetics experiments are drastically needed in order to establish 
efficient drug administration protocols in animal models. Nevertheless, we developped pre-clinical 
models demonstrating that cambinol protects mice from endotoxic shock and lethal K. pneumoniae 
infection. Although we should extend our analyses of the pathophysiological parameters in septic 
animals and verify that cambinol impairs host defenses to otherwise non-lethal infection, our 
preliminary data with cambinol miror the ones obtained using HDACi. Therefore, the same concerns 
about the utilization of HDACi (i.e. increasing susceptibility to infection particularly in 
immunodeficient patients) may apply to sirtuin inhibitors, especially since several sirtuin inhibitors 
have enterred phase II clinicals trials. 
 
HADCi and surtuin inhibitors have very promising therapeutic potential for the treatment of a 
large spectrum of diseases. Our present data suggest that these drugs may increase the susceptibility to 
infections, especially in the immunocompromissed host. A possible way to avoid these potential 
adverse effects is to persue the development of new generation isoform-specific inhibitors, which may 
lead to the discovery of inhibitors selectively blocking the pathological action of HDACs without 
interfering with antimicrobial host defences. 
